

Vicente Soriano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4609580/publications.pdf>

Version: 2024-02-01

806
papers

32,105
citations

5896

81
h-index

10158

140
g-index

859
all docs

859
docs citations

859
times ranked

18851
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of hepatitis delta and <scp>HIV</scp> infection. Liver International, 2023, 43, 108-115.	3.9	4
2	Trends in hospitalizations and deaths in HIV-infected patients in Spain over two decades. Aids, 2022, 36, 249-256.	2.2	7
3	Ultra-long-acting (XLA) antivirals for chronic viral hepatitis. International Journal of Infectious Diseases, 2022, 114, 45-50.	3.3	11
4	Another patient has cured HIV infection. AIDS Reviews, 2022, 23, 226-227.	1.0	0
5	A greater virulent HIV-1 subtype B variant has circulated in The Netherlands since the 1990’s. AIDS Reviews, 2022, 24, 50.	1.0	0
6	Use of antibiotics in respiratory viral infections. Internal and Emergency Medicine, 2022, 17, 1569-1570.	2.0	2
7	Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process. HIV Medicine, 2022, 23, 639-649.	2.2	3
8	Hepatitis C hospitalizations in Spain and impact of new curative antiviral therapies. Journal of Viral Hepatitis, 2022, 29, 777-784.	2.0	6
9	The unexpected high prevalence of HBV subgenotype D4 in patients with chronic hepatitis B in Galicia, a northwestern Spanish region, reflects strong links with Latin America. Journal of Clinical Virology, 2022, 153, 105195.	3.1	0
10	Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain. Hepatology International, 2022, 16, 1161-1169.	4.2	4
11	Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases. Future Microbiology, 2022, 17, 887-897.	2.0	6
12	Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions. AIDS Reviews, 2021, 22, 44-56.	1.0	10
13	Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Adults in Madrid, Spain. Clinical Infectious Diseases, 2021, 72, 1101-1102.	5.8	15
14	COVID-19 Comes 40 Years After AIDS - Any Lesson?. AIDS Reviews, 2021, 22, 63-77.	1.0	4
15	Clinical Outcome in Human T-Lymphotropic Virus Type 2 Carriers Following Organ Transplantation. Transplantation Proceedings, 2021, 53, 743-745.	0.6	1
16	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Setting-specific Transmission Rates: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2021, 73, e754-e764.	5.8	160
17	Situaci3n epidemiol3gica actual de la infecci3n por VIH-2 y HTLV-1 en EspaAa. Medicina ClAnica, 2021, 156, 290-296.	0.6	1
18	The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. AIDS Reviews, 2021, 23, 40-47.	1.0	66

#	ARTICLE	IF	CITATIONS
19	Current epidemiological status of HIV-2 and HTLV-1 infection in Spain. Medicina Clínica (English) 147, 2021, 1078-1082.	0.784	14
20	New SARS-CoV-2 Variants Challenge Vaccines Protection. AIDS Reviews, 2021, 23, 57-58.	1.0	8
21	Main differences between the first and second waves of COVID-19 in Madrid, Spain. International Journal of Infectious Diseases, 2021, 105, 374-376.	3.3	92
22	The time to offer treatments for COVID-19. Expert Opinion on Investigational Drugs, 2021, 30, 505-518.	4.1	20
23	Considerations on HTLV-1 infection in Spain. Medicina Clínica (English Edition), 2021, 156, 578.	0.2	0
24	COVID-19 in Madrid: Leading Pandemic Control after being the Spanish Epicenter. AIDS Reviews, 2021, 23, 115-116.	1.0	0
25	Third wave of COVID-19 in Madrid, Spain. International Journal of Infectious Diseases, 2021, 107, 212-214.	3.3	38
26	Consideraciones sobre la infección por HTLV-1 en España. Medicina Clínica, 2021, 156, 578.	0.6	0
27	Hepatitis delta in patients hospitalized in Spain (1997-2018). Aids, 2021, 35, 2311-2318.	2.2	7
28	Short Communication: Impact of COVID-19 on Case Reporting for HTLV and HIV-2 in Spain. AIDS Research and Human Retroviruses, 2021, 37, 610-612.	1.1	6
29	Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain. International Journal of Infectious Diseases, 2021, 112, 81-88.	3.3	21
30	Envisioning a hepatitis delta cure with new antivirals. Future Microbiology, 2021, 16, 927-930.	2.0	8
31	Unveiling Long COVID-19 Disease. AIDS Reviews, 2021, 22, 227-228.	1.0	6
32	A Key Action Plan for EDUCATION in a Global Crisis. Lecture Notes in Educational Technology, 2021, , 263-272.	0.8	0
33	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 628-639.	3.0	7
34	Tough requirements for new antiretroviral drugs. Lancet HIV, 2020, 7, e150-e151.	4.7	2
35	The Resurgence of Medical Ethics During the Coronavirus Disease (COVID)-19 Outbreak. AIDS Reviews, 2020, 22, 123-124.	1.0	3
36	Very Long-acting Antivirals as Chemovaccines for Preventing Viral Infections. AIDS Reviews, 2020, 22, 124-127.	1.0	2

#	ARTICLE	IF	CITATIONS
37	Long-acting antiretroviral therapy. <i>Nature Materials</i> , 2020, 19, 826-827.	27.5	16
38	Advances in hepatitis B therapeutics. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612096502.	1.8	26
39	Keeping alive enterprises while embracing unprecedented COVID-19 restrictions. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612092017.	1.8	4
40	Hospital admissions in individuals with HTLV-1 infection in Spain. <i>Aids</i> , 2020, 34, 1019-1027.	2.2	20
41	Inoculum at the time of SARS-CoV-2 exposure and risk of disease severity. <i>International Journal of Infectious Diseases</i> , 2020, 97, 290-292.	3.3	97
42	Why such excess of mortality for COVID-19 in Spain?. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612093275.	1.8	16
43	Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2. <i>Journal of Infectious Diseases</i> , 2020, 221, 1962-1972.	4.0	14
44	Multiple recombinant events in human T-cell Leukemia virus Type 1: complete sequences of recombinant African strains. <i>Emerging Microbes and Infections</i> , 2020, 9, 913-923.	6.5	9
45	HTLV-1 infection and health outcomes. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 407-408.	9.1	8
46	Coronavirus and other airborne agents with pandemic potential. <i>Current Opinion in Environmental Science and Health</i> , 2020, 17, 41-48.	4.1	9
47	Rapid antigen Testing and Mask Wearing While Waiting for COVID-19 Vaccines. <i>AIDS Reviews</i> , 2020, 22, 168-172.	1.0	3
48	Overt and occult hepatitis B among immigrants and native blood donors in Madrid, Spain. <i>Therapeutic Advances in Infectious Disease</i> , 2020, 7, 204993612098212.	1.8	3
49	Acute Viral Hepatitis in Men Having Sex with Men. <i>AIDS Reviews</i> , 2020, 22, 168-172.	1.0	0
50	HTLV-1 infection in solid organ transplant donors and recipients in Spain. <i>BMC Infectious Diseases</i> , 2019, 19, 706.	2.9	20
51	HTLV testing of solid organ transplant donors. <i>Clinical Transplantation</i> , 2019, 33, e13670.	1.6	8
52	Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppressors and failure of antiretrovirals. <i>Therapeutic Advances in Infectious Disease</i> , 2019, 6, 204993611986802.	1.8	7
53	Screening for retroviruses and hepatitis viruses using dried blood spots reveals a high prevalence of occult hepatitis B in Ghana. <i>Therapeutic Advances in Infectious Disease</i> , 2019, 6, 204993611985146.	1.8	7
54	JÃ©rÃ©me Lejeune passed away 25 years ago. <i>Hereditas</i> , 2019, 156, 18.	1.4	2

#	ARTICLE	IF	CITATIONS
55	Update of the statements on biology and clinical impact of occult hepatitis B virus infection. Journal of Hepatology, 2019, 71, 397-408.	3.7	341
56	HIV co-infection in HTLV-1 carriers in Spain. Virus Research, 2019, 266, 48-51.	2.2	14
57	Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain. Open Forum Infectious Diseases, 2019, 6, ofz036.	0.9	8
58	Hepatitis Delta Estimates in the United States Revisited. Clinical Infectious Diseases, 2019, 69, 1833-1834.	5.8	1
59	Predictors of Hepatitis C Treatment Failure After Using Direct-Acting Antivirals in People Living With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2019, 6, ofz070.	0.9	20
60	Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain. Journal of Antimicrobial Chemotherapy, 2019, 74, 1357-1362.	3.0	16
61	Occult hepatitis B and HIV infection. European Journal of Gastroenterology and Hepatology, 2019, 31, 1403-1407.	1.6	12
62	Treatment outcome in dually HIV-1 and HIV-2 coinfecting patients living in Spain. Aids, 2019, 33, 2167-2172.	2.2	7
63	Rebound in Sexually Transmitted Infections Following the Success of Antiretrovirals for HIV/AIDS. AIDS Reviews, 2019, 20, 187-204.	1.0	15
64	HTLV-1 Infection is Rising Up in Spain Whereas HTLV-2 is Vanishing. AIDS Reviews, 2019, 21, 233-235.	1.0	4
65	Decline and Changing Profile of Hepatitis Delta among Injection Drug users in Spain. Antiviral Therapy, 2018, 23, 87-90.	1.0	16
66	Prevention of liver cancer with new curative hepatitis C antivirals: Real-world challenges. Cancer, 2018, 124, 1647-1649.	4.1	13
67	Hepatitis Delta Enters a New Therapeutic Era. Journal of Infectious Diseases, 2018, 217, 1173-1176.	4.0	8
68	Treatment and prevention of HIV infection with long-acting antiretrovirals. Expert Review of Clinical Pharmacology, 2018, 11, 507-517.	3.1	38
69	Short article: Hepatitis delta in patients with resolved hepatitis B virus infection. European Journal of Gastroenterology and Hepatology, 2018, 30, 1063-1065.	1.6	8
70	Increased Indoleamine-2,3-Dioxygenase Activity Is Associated With Poor Clinical Outcome in Adults Hospitalized With Influenza in the INSIGHT FLU003Plus Study. Open Forum Infectious Diseases, 2018, 5, ofx228.	0.9	11
71	AIDS Clinical Research in Spain—Large HIV Population, Geniality of Doctors, and Missing Opportunities. Viruses, 2018, 10, 293.	3.3	9
72	Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain. European Journal of Gastroenterology and Hepatology, 2018, 30, 1060-1062.	1.6	20

#	ARTICLE	IF	CITATIONS
73	Report from the International Conference on Viral Hepatitis (ICVH) – Chicago, October 2017. AIDS Reviews, 2018, 20, .	1.0	18
74	Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16-18 May 2018, Marseille, France: from HIV and comorbidities to global health. Journal of Virus Eradication, 2018, 4, 196-207.	0.5	1
75	Report from the International Conference on Viral Hepatitis - 2017. AIDS Reviews, 2018, 20, 58-70.	1.0	5
76	Hepatitis B Gene Therapy Coming to Age. AIDS Reviews, 2018, 20, 125-127.	1.0	5
77	Rate and Predictors of Treatment Failure to All-Oral HCV Regimens outside Clinical Trials. Antiviral Therapy, 2017, 22, 307-312.	1.0	50
78	Human T-Lymphotropic Virus Infection in Hepatitis C Virus –Antibody Positive Patients in Spain. AIDS Research and Human Retroviruses, 2017, 33, 1013-1017.	1.1	0
79	HIV type 2 epidemic in Spain. Aids, 2017, 31, 1353-1364.	2.2	18
80	Human T-lymphotropic virus type 1 infection and disease in Spain. Aids, 2017, 31, 1653-1663.	2.2	30
81	Hepatitis delta and HIV infection. Aids, 2017, 31, 875-884.	2.2	35
82	Dual antiretroviral therapy for HIV infection. Expert Opinion on Drug Safety, 2017, 16, 923-932.	2.4	47
83	Characterization of Free Phenytoin Concentrations in End-Stage Renal Disease Using the Winter-Tozer Equation. Annals of Pharmacotherapy, 2017, 51, 669-674.	1.9	15
84	New antivirals for the treatment of chronic hepatitis B. Expert Opinion on Investigational Drugs, 2017, 26, 843-851.	4.1	43
85	Treatment of hepatitis C with new fixed dose combinations. Expert Opinion on Pharmacotherapy, 2017, 18, 1235-1242.	1.8	23
86	Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response. Journal of Antimicrobial Chemotherapy, 2017, 72, 2083-2088.	3.0	27
87	Antiretroviral treatment of HIV-2 infection. Future Virology, 2017, 12, 461-472.	1.8	4
88	Need to Face Liver Cirrhosis after HCV Cure with Antivirals. EBioMedicine, 2017, 24, 24-25.	6.1	6
89	Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 1015-1022.	3.3	13
90	Is Ribavirin Teratogenic in Humans? No Evidence So Far. Drug Safety, 2017, 40, 1163-1165.	3.2	2

#	ARTICLE	IF	CITATIONS
91	Drug interactions in HIV-infected patients treated for hepatitis C. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 807-816.	3.3	16
92	Impact of <i>ITPA</i> Gene Polymorphisms on the Risk of Ribavirin-Induced Haemolytic Anaemia using Interferon-Free Antivirals for Chronic Hepatitis C. Antiviral Therapy, 2017, 22, 571-575.	1.0	6
93	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2869-2878.	3.0	17
94	Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach. PLoS ONE, 2017, 12, e0184329.	2.5	6
95	Transmission of Multi-Drug Resistant HIV-1 Despite Antiretroviral Prophylaxis. AIDS Reviews, 2017, 19, 54-55.	1.0	3
96	A New HIV Paradigm: Dual Antiretroviral Regimens as Maintenance Therapy. AIDS Reviews, 2017, 19, 113-114.	1.0	1
97	Hepatitis A Outbreaks in European Homosexual Men. AIDS Reviews, 2017, 19, 113-114.	1.0	8
98	Hepatic Decompensation with Sofosbuvir plus Simeprevir in a Patient with Child-Pugh B Compensated Cirrhosis. Antiviral Therapy, 2016, 21, 91-92.	1.0	18
99	Highlights from the 2016 International Symposium on HIV & Emerging Infectious Diseases (ISHEID). Journal of Virus Eradication, 2016, 2, 187-192.	0.5	0
100	HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) AND HUMAN T-LYMPHOTROPIC VIRUS 2 (HTLV-2): GEOGRAPHICAL RESEARCH TRENDS AND COLLABORATION NETWORKS (1989-2012). Revista Do Instituto De Medicina Tropical De Sao Paulo, 2016, 58, 11.	1.1	11
101	<i>IL15</i> polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection. Liver International, 2016, 36, 1258-1266.	3.9	5
102	Tenofovir for Hepatitis Delta. Hepatology, 2016, 63, 1395-1396.	7.3	8
103	Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1197-1209.	3.3	41
104	Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. European Journal of Gastroenterology and Hepatology, 2016, 28, 923-926.	1.6	1
105	Hypoglycemia in a diabetic patient during hepatitis C therapy. Hepatology, 2016, 63, 2065-2066.	7.3	16
106	Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfecting patients. Journal of Translational Medicine, 2016, 14, 257.	4.4	20
107	Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. Journal of Infection, 2016, 72, 587-596.	3.3	60
108	Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opinion on Pharmacotherapy, 2016, 17, 1215-1223.	1.8	53

#	ARTICLE	IF	CITATIONS
109	Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in <scp>HIV</scp>-positive patients. Journal of Viral Hepatitis, 2016, 23, 47-52.	2.0	57
110	High Serum HCV RNA in Chronic Hepatitis C Patients Coinfected with HIV despite Successful Antiretroviral Therapy. Antiviral Therapy, 2016, 21, 489-494.	1.0	6
111	Is HIV still a special population for the treatment of hepatitis C?. Aids, 2016, 30, 2001-2003.	2.2	4
112	Infection-related and -unrelated malignancies, <scp>HIV</scp> and the aging population. HIV Medicine, 2016, 17, 590-600.	2.2	37
113	The global spread of HIV-1 subtype B epidemic. Infection, Genetics and Evolution, 2016, 46, 169-179.	2.3	60
114	Acute hepatitis C virus re-infection in a heterosexual <scp>HIV</scp>-positive partner. Liver International, 2016, 36, 763-763.	3.9	5
115	Host and disease factors are associated with cognitive function in European <scp>HIV</scp>-infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 2016, 17, 471-478.	2.2	7
116	SOLAR-2: the sun also rises for cirrhotics. Lancet Infectious Diseases, The, 2016, 16, 624-625.	9.1	1
117	Delta hepatitis: new approaches to therapy. Future Virology, 2016, 11, 197-205.	1.8	0
118	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 1056-1062.	3.0	22
119	New hepatitis C therapies for special patient populations. Expert Opinion on Pharmacotherapy, 2016, 17, 217-229.	1.8	22
120	Short Communication: <i>CXCL12</i> rs1029153 Polymorphism Is Associated with the Sustained Virological Response in HIV/Hepatitis C Virus-Coinfected Patients on Hepatitis C Virus Therapy. AIDS Research and Human Retroviruses, 2016, 32, 226-231.	1.1	0
121	MicroRNA Profile in CD8+ T-Lymphocytes from HIV-Infected Individuals: Relationship with Antiviral Immune Response and Disease Progression. PLoS ONE, 2016, 11, e0155245.	2.5	22
122	Highlights from the 2016 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): 25-27 May, Marseille, France. Journal of Virus Eradication, 2016, 2, 187-92.	0.5	0
123	Report from the International Conference on Viral Hepatitis (ICVH), San Francisco, March 2016. AIDS Reviews, 2016, 18, 81-8.	1.0	1
124	Reactivation of Hepatitis B in HIV Patients Treated for Hepatitis C. AIDS Reviews, 2016, 18, 222-223.	1.0	4
125	Liver Fibrosis Progression despite HCV Cure with Antiviral Therapy in HIV-HCV-Coinfected Patients. Antiviral Therapy, 2015, 20, 329-334.	1.0	16
126	Corrigendum. HIV Clinical Trials, 2015, 16, 236-238.	2.0	0

#	ARTICLE	IF	CITATIONS
127	Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients. <i>Current Opinion in HIV and AIDS</i> , 2015, 10, 309-315.	3.8	24
128	IFNL4 rs368234815 polymorphism is associated with innate resistance to HIV-1 infection. <i>Aids</i> , 2015, 29, 1895-1897.	2.2	19
129	Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study. <i>PLoS ONE</i> , 2015, 10, e0139981.	2.5	45
130	Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: a randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. <i>HIV Clinical Trials</i> , 2015, 16, 72-80.	2.0	8
131	Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 179-186.	1.8	7
132	TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfecting patients. <i>Journal of Clinical Virology</i> , 2015, 65, 62-67.	3.1	6
133	Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naïve Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1282-1291.	3.2	10
134	Dolutegravir for the treatment of HIV-2 infection. <i>Journal of Clinical Virology</i> , 2015, 64, 12-15.	3.1	30
135	Drug interactions with new hepatitis C oral drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 333-341.	3.3	46
136	Differential regulation of cytotoxicity pathway discriminating between HIV, HCV mono- and co-infection identified by transcriptome profiling of PBMCs. <i>Virology Journal</i> , 2015, 12, 4.	3.4	4
137	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. <i>PLoS Medicine</i> , 2015, 12, e1001809.	8.4	119
138	Emerging Challenges in Managing Hepatitis B in HIV Patients. <i>Current HIV/AIDS Reports</i> , 2015, 12, 344-352.	3.1	23
139	Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. <i>Clinical Microbiology and Infection</i> , 2015, 21, 1027-1032.	6.0	12
140	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001810.	8.4	188
141	Hepatitis C seroconversions in <scp>HIV</scp> infection across Europe: which regions and patient groups are affected?. <i>Liver International</i> , 2015, 35, 2384-2391.	3.9	33
142	Faldaprevir and pegylated interferon α -2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. <i>Aids</i> , 2015, 29, 571-581.	2.2	17
143	Dual antiviral therapy for HIV and hepatitis C “ drug interactions and side effects. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1421-1434.	2.4	17
144	Changing utilization of Stavudine (d4T) in HIV-positive people in 2006–2013 in the EuroSIDA study. <i>HIV Medicine</i> , 2015, 16, 533-543.	2.2	11

#	ARTICLE	IF	CITATIONS
145	Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. Journal of Clinical Virology, 2015, 71, 63-66.	3.1	12
146	Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: <sc>SOUND</sc>â€³, a Phase 2b study. Liver International, 2015, 35, 417-421.	3.9	18
147	Gene therapy for HIV infection. Expert Opinion on Biological Therapy, 2015, 15, 319-327.	3.1	8
148	ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection. PLoS ONE, 2015, 10, e0144004.	2.5	5
149	Caution with new oral hepatitis C drugs. AIDS Reviews, 2015, 17, 121-2.	1.0	5
150	The Burden of Neglected HIV-2 and HTLV-1 Infections in Spain. AIDS Reviews, 2015, 17, 212-9.	1.0	9
151	Non-Human Cancers in AIDS Patients. AIDS Reviews, 2015, 17, 238-9.	1.0	0
152	IFNL4 ss469415590 Variant Shows Similar Performance to rs12979860 as Predictor of Response to Treatment against Hepatitis C Virus Genotype 1 or 4 in Caucasians. PLoS ONE, 2014, 9, e95515.	2.5	24
153	Incidence of Hepatitis C Virus (HCV) in a Multicenter Cohort of HIV-Positive Patients in Spain 2004â€³2011: Increasing Rates of HCV Diagnosis but Not of HCV Seroconversions. PLoS ONE, 2014, 9, e116226.	2.5	19
154	Very Late HCV Relapse following Triple Therapy for Hepatitis C. Antiviral Therapy, 2014, 19, 723-724.	1.0	5
155	Management and treatment of chronic hepatitis B in HIV-positive patients. Annals of Medicine, 2014, 46, 290-296.	3.8	11
156	Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. International Journal of Tuberculosis and Lung Disease, 2014, 18, 700-708.	1.2	11
157	A polymorphism linked to <i><sc>RRAS</sc></i>, <i><sc>SCAF</sc>1</i>, <i><sc>IRF</sc>3</i> and <i><sc>BCL</sc>2L12</i> genes is associated with cirrhosis in hepatitis C virus carriers. Liver International, 2014, 34, 558-566.	3.9	9
158	Changes in liver fibrosis in <sc>HIV</sc>/<sc>HCV</sc>-coinfected patients following different outcomes with peginterferon plus ribavirin therapy. Journal of Viral Hepatitis, 2014, 21, 475-479.	2.0	16
159	Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. Aids, 2014, 28, 2389-2394.	2.2	56
160	HIV-2 viral tropism influences CD4+ T cell count regardless of viral load. Journal of Antimicrobial Chemotherapy, 2014, 69, 2191-2194.	3.0	5
161	PPARÎ³2 Pro12Ala Polymorphism Is Associated With Sustained Virological Response in HIV/HCV-Coinfected Patients Under HCV Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 113-119.	2.1	5
162	X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. Aids, 2014, 28, 1603-1609.	2.2	14

#	ARTICLE	IF	CITATIONS
163	Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy. <i>Aids</i> , 2014, 28, 1473-1478.	2.2	24
164	Diagnosis of subclinical atherosclerosis in HIV-infected patients: higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms. <i>European Journal of Preventive Cardiology</i> , 2014, 21, 739-748.	1.8	31
165	P750 SPONTANEOUS HCV CLEARANCE IN HIV PATIENTS WITH CHRONIC HEPATITIS C BEARING FAVORABLE IL28B ALLELES ON ANTIRETROVIRAL THERAPY. <i>Journal of Hepatology</i> , 2014, 60, S321.	3.7	0
166	Hepatitis Delta Is a Major Determinant of Liver Decompensation Events and Death in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2014, 58, 1549-1553.	5.8	85
167	High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance. <i>HIV Medicine</i> , 2014, 15, n/a-n/a.	2.2	4
168	European mitochondrial haplogroups are not associated with hepatitis <scp>C</scp> virus (<scp>HCV</scp>) treatment response in <scp>HIV</scp>/<scp>HCV</scp>-coinfected patients. <i>HIV Medicine</i> , 2014, 15, 425-430.	2.2	5
169	Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. <i>Journal of Infection</i> , 2014, 68, 372-377.	3.3	3
170	A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. <i>Infection</i> , 2014, 42, 757-762.	4.7	4
171	Dolutegravir, abacavir and lamivudine as HIV therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1051-1057.	1.8	10
172	Towards hepatitis C eradication from the HIV-infected population. <i>Antiviral Research</i> , 2014, 105, 1-7.	4.1	24
173	Emerging antiretroviral drugs. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 211-219.	1.8	19
174	Pharmacogenetics of antiretroviral therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1119-1130.	3.3	11
175	Molecular Epidemiology and Clinical Features of Human T Cell Lymphotropic Virus Type 1 Infection in Spain. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 856-862.	1.1	10
176	Progression to advanced liver fibrosis in HIV/HCV-coinfected patients and prioritization of new hepatitis C therapies. <i>Antiviral Therapy</i> , 2014, 19, 799-803.	1.0	9
177	Long-term survival and liver-related events after peginterferon/ribavirin therapy in HIV-infected patients with chronic hepatitis C. <i>Antiviral Therapy</i> , 2014, 20, 65-72.	1.0	16
178	ACSM4 Polymorphisms Are Associated With Rapid AIDS Progression in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 65, 27-32.	2.1	8
179	Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. <i>PLoS ONE</i> , 2014, 9, e87160.	2.5	35
180	HIV-2 and HTLV-1 infections in Spain, a non-endemic region. <i>AIDS Reviews</i> , 2014, 16, 152-9.	1.0	8

#	ARTICLE	IF	CITATIONS
181	RNA viruses at the forefront of human infections - HIV, hepatitis C, and now Ebola. <i>AIDS Reviews</i> , 2014, 16, 246-7.	1.0	3
182	Hepatitis C therapy with HCV NS5B polymerase inhibitors. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1161-1170.	1.8	57
183	Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves. <i>Journal of Medical Virology</i> , 2013, 85, 1734-1740.	5.0	8
184	Update on HIV/HCV Coinfection. <i>Current HIV/AIDS Reports</i> , 2013, 10, 226-234.	3.1	48
185	Faldaprevir and Deleobuvir for HCV Genotype 1 Infection. <i>New England Journal of Medicine</i> , 2013, 369, 630-639.	27.0	215
186	Strategic use of lamivudine in the management of chronic hepatitis B. <i>Antiviral Research</i> , 2013, 100, 435-438.	4.1	15
187	Treatment of Hepatitis C in HIV Patients in the New Era of Direct-Acting Antivirals. <i>Current Hepatitis Reports</i> , 2013, 12, 269-275.	0.3	3
188	Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. <i>Journal of Infection</i> , 2013, 67, 59-64.	3.3	10
189	Genetic Determinants of Idiopathic Noncirrhotic Portal Hypertension in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2013, 56, 1117-1122.	5.8	27
190	Association between HLA alleles and HAM/TSP in individuals infected with HTLV-1. <i>Journal of Neurology</i> , 2013, 260, 2551-2555.	3.6	21
191	HIV gag-specific immune response mediated by double negative (CD3 ⁺ CD4 ⁺ CD8 ⁺) T cells in HIV-exposed seronegative individuals. <i>Journal of Medical Virology</i> , 2013, 85, 200-209.	5.0	11
192	Hepatitis B in HIV-Infected Patients. <i>Clinics in Liver Disease</i> , 2013, 17, 489-501.	2.1	24
193	Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?. <i>Journal of Hepatology</i> , 2013, 59, 213-220.	3.7	41
194	Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. <i>Journal of Clinical Virology</i> , 2013, 58, 391-395.	3.1	10
195	Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library. <i>European Journal of Immunology</i> , 2013, 43, 499-509.	2.9	16
196	Antiretroviral drug-related toxicities – clinical spectrum, prevention, and management. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 697-707.	2.4	23
197	IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus/HCV coinfected patients. <i>Journal of Viral Hepatitis</i> , 2013, 20, 358-366.	2.0	17
198	The changing face of hepatitis C in the new era of direct-acting antivirals. <i>Antiviral Research</i> , 2013, 97, 36-40.	4.1	24

#	ARTICLE	IF	CITATIONS
199	HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. <i>Aids</i> , 2013, 27, 1231-1238.	2.2	15
200	Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. <i>Aids</i> , 2013, 27, 2219-2224.	2.2	15
201	Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. <i>Aids</i> , 2013, 27, 81-85.	2.2	55
202	Hepatitis C Therapy: Highlights From the 2012 Annual Meeting of the European Association for the Study of the Liver. <i>Clinical Infectious Diseases</i> , 2013, 56, 560-566.	5.8	20
203	Hepatitis B, C, and D and HIV Infections among Immigrants from Equatorial Guinea Living in Spain. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 789-794.	1.4	27
204	HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein. <i>Aids</i> , 2013, 27, 1375-1385.	2.2	15
205	Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients. <i>Aids</i> , 2013, 27, 181-189.	2.2	53
206	Chronic Hepatitis E in HIV Patients: Rapid Progression to Cirrhosis and Response to Oral Ribavirin. <i>Clinical Infectious Diseases</i> , 2013, 57, 465-468.	5.8	96
207	Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1994-2002.	3.0	9
208	Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1517-1527.	3.9	18
209	Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2616-2625.	3.0	14
210	A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 915-921.	3.0	4
211	Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. <i>HIV Medicine</i> , 2013, 14, 614-623.	2.2	46
212	Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. <i>Liver International</i> , 2013, 33, 1357-1362.	3.9	45
213	Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy. <i>HIV Medicine</i> , 2013, 14, 370-378.	2.2	16
214	Pharmacokinetics of new oral hepatitis C antiviral drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 5-16.	3.3	15
215	Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of peginterferon-ribavirin therapy. <i>Antiviral Therapy</i> , 2013, 19, 287-292.	1.0	6
216	Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients. <i>Aids</i> , 2013, 27, 1187-1188.	2.2	22

#	ARTICLE	IF	CITATIONS
217	Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. <i>Aids</i> , 2013, 27, 2715-2724.	2.2	7
218	Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. <i>Aids</i> , 2013, 27, 1129-1134.	2.2	24
219	Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients. <i>Aids</i> , 2013, 27, 687-696.	2.2	10
220	Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. <i>Aids</i> , 2013, 27, 2001.	2.2	19
221	Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. <i>Aids</i> , 2013, 27, 163-173.	2.2	12
222	Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. <i>Antiviral Therapy</i> , 2013, 18, 709-715.	1.0	12
223	Very Late Relapse after Discontinuation of Antiviral Therapy for Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 1033-1035.	1.0	10
224	Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. <i>PLoS ONE</i> , 2013, 8, e64283.	2.5	25
225	Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV. <i>Annals of Internal Medicine</i> , 2013, 159, 86-96.	3.9	179
226	The changing epidemiology of liver disease in HIV patients. <i>AIDS Reviews</i> , 2013, 15, 25-31.	1.0	38
227	Cardiovascular Disease Risk in HIV Infection and Endothelial Progenitor Cells. <i>Journal of Infectious Diseases</i> , 2012, 206, 1479-1480.	4.0	3
228	Antiviral effect of raltegravir on HTLV-1 carriers. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 218-221.	3.0	39
229	Inpatient and Outpatient Pharmacokinetic Variability of Raltegravir in the Clinical Setting. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 232-235.	2.0	30
230	Development of Tropical Spastic Paraparesis in Human T-Lymphotropic Virus Type 1 Carriers Is Influenced by Interleukin 28B Gene Polymorphisms. <i>Clinical Infectious Diseases</i> , 2012, 55, e1-e4.	5.8	25
231	Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2873-2878.	3.2	62
232	Management and Treatment of Chronic Hepatitis C in HIV Patients. <i>Seminars in Liver Disease</i> , 2012, 32, 138-146.	3.6	25
233	HIV and Liver Disease. <i>Seminars in Liver Disease</i> , 2012, 32, 101-102.	3.6	0
234	Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1007-1014.	1.8	14

#	ARTICLE	IF	CITATIONS
235	Short Communication: Does Interleukin-28B Single Nucleotide Polymorphisms Influence the Natural History of Hepatitis B?. AIDS Research and Human Retroviruses, 2012, 28, 1262-1264.	1.1	13
236	Prevalence of Xenotropic Murine Leukemia Virus-Related Virus Infection in Different Risk Populations in Spain. AIDS Research and Human Retroviruses, 2012, 28, 1089-1094.	1.1	6
237	Short Communication High Risk of Endothelial Dysfunction in HIV Individuals May Result from Deregulation of Circulating Endothelial Cells and Endothelial Progenitor Cells. AIDS Research and Human Retroviruses, 2012, 28, 656-659.	1.1	17
238	Drug resistance testing in hepatitis C therapy. Future Virology, 2012, 7, 309-321.	1.8	9
239	Plasma Raltegravir Exposure Influences the Antiviral Activity and Selection of Resistance Mutations. AIDS Research and Human Retroviruses, 2012, 28, 156-164.	1.1	18
240	Comparison of HIV-1 RNA Measurements Obtained by Using Plasma and Dried Blood Spots in the Automated Abbott Real-Time Viral Load Assay. Journal of Clinical Microbiology, 2012, 50, 569-572.	3.9	41
241	Short Communication: RNASEL Alleles and Susceptibility to Infection by Human Retroviruses and Hepatitis Viruses. AIDS Research and Human Retroviruses, 2012, 28, 1259-1261.	1.1	2
242	Pharmacogenetics of hepatitis C. Journal of Antimicrobial Chemotherapy, 2012, 67, 523-529.	3.0	30
243	Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. Aids, 2012, 26, 1387-1392.	2.2	64
244	Prevalence of Natural Polymorphisms at the HCV Ns5A Gene Associated with Resistance to Daclatasvir, An Ns5A Inhibitor. Antiviral Therapy, 2012, 17, 921-926.	1.0	44
245	B3â€fIdentification of Neutralizing Antibodies and Their Epitopes From HIV Controllers. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 74.	2.1	0
246	Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. Aids, 2012, 26, 551-557.	2.2	9
247	Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. Aids, 2012, 26, 1917-1926.	2.2	62
248	Variants in the ITPA Gene Protect Against Ribavirin-Induced Hemolytic Anemia in HIV/HCV-Coinfected Patients With All HCV Genotypes. Journal of Infectious Diseases, 2012, 205, 376-383.	4.0	31
249	Author's response: expert reviews: who are they for?. Expert Opinion on Pharmacotherapy, 2012, 13, 1217-1218.	1.8	0
250	Treatment failure with new hepatitis C drugs. Expert Opinion on Pharmacotherapy, 2012, 13, 313-323.	1.8	30
251	Efficacy and safety of rilpivirine in treatment-naïve, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. Journal of Antimicrobial Chemotherapy, 2012, 67, 2020-2028.	3.0	35
252	A New Era for Hepatitis Câ€™New Diagnostics Tools and New Weapons. ACS Medicinal Chemistry Letters, 2012, 3, 440-441.	2.8	5

#	ARTICLE	IF	CITATIONS
253	Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. <i>Journal of Hepatology</i> , 2012, 56, 788-794.	3.7	34
254	Different impact of IL28B polymorphisms on response to peginterferon- α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. <i>Journal of Clinical Virology</i> , 2012, 55, 58-61.	3.1	12
255	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. <i>Retrovirology</i> , 2012, 9, 68.	2.0	7
256	Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure. <i>AIDS Research and Therapy</i> , 2012, 9, 23.	1.7	2
257	Management of hepatitis C in HIV and/or HBV co-infected patients. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 517-530.	2.4	14
258	Treatment of Hepatitis C in Patients Infected with Human Immunodeficiency Virus in the Direct-Acting Antiviral Era. <i>Infectious Disease Clinics of North America</i> , 2012, 26, 931-948.	5.1	7
259	Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study. <i>PLoS ONE</i> , 2012, 7, e41673.	2.5	32
260	Long-Term Use of Atazanavir in the Treatment of HIV-Infected patients. <i>Clinical Medicine Insights Therapeutics</i> , 2012, 4, CMT.S5764.	0.4	2
261	Impact of IL28B gene polymorphisms on interferon- α 3 plasma levels during pegylated interferon- α /ribavirin therapy for chronic hepatitis C in patients coinfecting with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1246-1249.	3.0	27
262	No influence of antiretroviral therapy on the mutation rate of the HCV NS5B polymerase in HIV/HCV-coinfected patients. <i>Antiviral Research</i> , 2012, 95, 67-71.	4.1	2
263	Endothelial dysfunction in HIV infection—the role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages. <i>AIDS Reviews</i> , 2012, 14, 223-30.	1.0	34
264	Emerging viral infections—a potential threat for blood supply in the 21st century. <i>AIDS Reviews</i> , 2012, 14, 279-89.	1.0	24
265	Elite Controllers Display Higher Activation on Central Memory CD8 T Cells Than HIV Patients Successfully on HAART. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 157-165.	1.1	26
266	Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 457-477.	3.3	36
267	Seroprevalence of HTLV infection among immigrant pregnant women in the Mediterranean coast of Spain. <i>Journal of Clinical Virology</i> , 2011, 51, 192-194.	3.1	6
268	HTLV infection among foreign pregnant women living in Spain. <i>Journal of Clinical Virology</i> , 2011, 52, 119-122.	3.1	24
269	European guidelines on the clinical management of HIV-1 tropism testing. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 394-407.	9.1	218
270	The expansion ability but not the quality of HIV-specific CD8+ T cells is associated with protective human leucocyte antigen class I alleles in long-term non-progressors. <i>Immunology</i> , 2011, 134, 305-313.	4.4	4

#	ARTICLE	IF	CITATIONS
271	HBV primary drug resistance in newly diagnosed HIV/HBV-coinfected individuals in Spain. Antiviral Therapy, 2011, 16, 585-589.	1.0	18
272	Resistance data in the ARTEN trial. Antiviral Therapy, 2011, 16, 1135-1136.	1.0	1
273	A Highly Sensitive and Specific Model for Predicting HIV-1 Tropism in Treatment-Experienced Patients Combining Interpretation of V3 Loop Sequences and Clinical Parameters. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 51-58.	2.1	12
274	Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. Aids, 2011, 25, 269-271.	2.2	26
275	Hepatitis delta in HIV-infected individuals in Europe. Aids, 2011, 25, 1987-1992.	2.2	79
276	Noncirrhotic portal hypertension in HIV infection. Current Opinion in Infectious Diseases, 2011, 24, 12-18.	3.1	34
277	Host genetics. Current Opinion in HIV and AIDS, 2011, 6, 491-500.	3.8	5
278	Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV/hepatitis C virus-coinfected patients with prior nonresponse or relapse. Aids, 2011, 25, 1131-1133.	2.2	20
279	New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B. Aids, 2011, 25, 1013-1014.	2.2	11
280	Natural Polymorphisms Associated with Resistance to New Antivirals against HCV in Newly Diagnosed HIV/HCV-Coinfected Patients. Antiviral Therapy, 2011, 16, 413-416.	1.0	37
281	Hyaluronic Acid Levels Predict Increased Risk of Non-Aids Death in Hepatitis-Coinfected Persons Interrupting Antiretroviral Therapy in the Smart Study. Antiviral Therapy, 2011, 16, 667-675.	1.0	16
282	Nevirapine versus Atazanavir/Ritonavir, Each Combined with Tenofovir Disoproxil Fumarate/Emtricitabine, in Antiretroviral-Naïve HIV-1 Patients: The Arten Trial. Antiviral Therapy, 2011, 16, 339-348.	1.0	89
283	Predicted effect of direct acting antivirals in the current HIV/HCV-coinfected population in Spain. Antiviral Therapy, 2011, 17, 571-575.	1.0	13
284	Elevated TGF- β 1 levels might protect HCV/HIV-coinfected patients from liver fibrosis. European Journal of Clinical Investigation, 2011, 41, 70-76.	3.4	21
285	Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. Journal of Viral Hepatitis, 2011, 18, 11-16.	2.0	67
286	Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. Journal of Viral Hepatitis, 2011, 18, 325-330.	2.0	31
287	Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis. Journal of Viral Hepatitis, 2011, 18, 542-548.	2.0	3
288	Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. HIV Medicine, 2011, 12, 487-493.	2.2	16

#	ARTICLE	IF	CITATIONS
289	Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). HIV Medicine, 2011, 12, 374-382.	2.2	30
290	Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. Journal of Infection, 2011, 63, 382-390.	3.3	19
291	Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients – Impact of HIV subtypes and prior raltegravir experience. Antiviral Research, 2011, 90, 164-167.	4.1	48
292	Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressors. Clinical Immunology, 2011, 139, 110-114.	3.2	60
293	HCV and HIV Coinfection. Current Hepatitis Reports, 2011, 10, 52-61.	0.3	1
294	Changing Rate of Non-B Subtypes and Coinfection with Hepatitis B/C Viruses in Newly Diagnosed HIV Type 1 Individuals in Spain. AIDS Research and Human Retroviruses, 2011, 27, 633-638.	1.1	14
295	Short Communication: Use of Serum Bilirubin Levels as Surrogate Marker of Early Virological Response to Atazanavir-Based Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2011, 27, 1043-1045.	1.1	11
296	Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3 rd Cag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antiretroviral Therapy. Antimicrobial Agents and Chemotherapy, 2011, 55, 3729-3742.	3.2	23
297	Detection of hepatitis B virus genotype A3 and primary drug resistance mutations in African immigrants with chronic hepatitis B in Spain. Journal of Antimicrobial Chemotherapy, 2011, 66, 641-644.	3.0	15
298	Influence of Interleukin-28B Single-Nucleotide Polymorphisms on Progression to Liver Cirrhosis in Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Patients Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2011, 203, 1629-1636.	4.0	55
299	Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. Journal of Antimicrobial Chemotherapy, 2011, 66, 2838-2842.	3.0	19
300	An International Collaboration To Standardize HIV-2 Viral Load Assays: Results from the 2009 ACHI E V 2E Quality Control Study. Journal of Clinical Microbiology, 2011, 49, 3491-3497.	3.9	29
301	Drug resistance mutations in patients infected with HIV-2 living in Spain. Journal of Antimicrobial Chemotherapy, 2011, 66, 1484-1488.	3.0	29
302	Genetic Variants of ABCC10, a Novel Tenofovir Transporter, Are Associated With Kidney Tubular Dysfunction. Journal of Infectious Diseases, 2011, 204, 145-153.	4.0	102
303	Impact of Inosine Triphosphatase Gene Variants on the Risk of Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated for Chronic Hepatitis C. Clinical Infectious Diseases, 2011, 53, 1291-1295.	5.8	16
304	Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and Ritonavir-Boosted Protease Inhibitors in Treatment-Naïve HIV-2-Infected Patients: The ACHIEV2E Collaboration Study Group. Clinical Infectious Diseases, 2011, 52, 1257-1266.	5.8	41
305	Directly acting antivirals against hepatitis C virus. Journal of Antimicrobial Chemotherapy, 2011, 66, 1673-1686.	3.0	81
306	Challenges and opportunities for hepatitis C drug development in HIV/hepatitis C virus-co-infected patients. Aids, 2011, 25, 2197-2208.	2.2	33

#	ARTICLE	IF	CITATIONS
307	Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. <i>Aids</i> , 2011, 25, 73-79.	2.2	74
308	Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. <i>Aids</i> , 2011, 25, 761-766.	2.2	26
309	High Concordance between the Position-Specific Scoring Matrix and Geno2pheno Algorithms for Genotypic Interpretation of HIV-1 Tropism: V3 Length as the Major Cause of Disagreement. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3380-3382.	3.9	18
310	Short Communication: Severe Immune Suppression in Patients Infected with R5-Tropic HIV-1 Strains Is Associated with Increased gp120 Net Charge at Variable Regions. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 965-967.	1.1	9
311	Impact of Baseline HIV-1 Tropism on Viral Response and CD4 Cell Count Gains in HIV-Infected Patients Receiving First-line Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 139-144.	4.0	32
312	A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. <i>Journal of Infectious Diseases</i> , 2011, 204, 741-752.	4.0	19
313	Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. <i>Aids</i> , 2011, 25, 399-409.	2.2	126
314	Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings. <i>Aids</i> , 2010, 24, 1171-1176.	2.2	84
315	Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. <i>Aids</i> , 2010, 24, 469-471.	2.2	13
316	Frequent hepatitis B virus rebound among HIV&€“hepatitis B virus-coinfected patients following antiretroviral therapy interruption. <i>Aids</i> , 2010, 24, 857-865.	2.2	59
317	High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. <i>Aids</i> , 2010, 24, 467-469.	2.2	34
318	Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. <i>Aids</i> , 2010, 24, 1064-1066.	2.2	120
319	Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 881-886.	1.0	35
320	Viral hepatitis and HIV co-infection. <i>Antiviral Research</i> , 2010, 85, 303-315.	4.1	177
321	Drastic decrease of transcription activity due to hypermutated long terminal repeat (LTR) region in different HIV-1 subtypes and recombinants. <i>Antiviral Research</i> , 2010, 88, 152-159.	4.1	11
322	Tenofovir (TDF) containing first-line HAART is associated with changes in plasma parameters suggestive of increased bone resorption. <i>Retrovirology</i> , 2010, 7, .	2.0	0
323	Glomerular filtration (GF) determined by creatinine clearance (CCR) in 24 hours urine and cockcroft & gault (cg) and modification of diet in renal disease (MDRD) equations in a large cohort of HIV+ patients. <i>Retrovirology</i> , 2010, 7, .	2.0	0
324	Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes. <i>Journal of Viral Hepatitis</i> , 2010, 17, 866-871.	2.0	2

#	ARTICLE	IF	CITATIONS
325	Drug Resistance Mutations in HIV-Infected Patients in the Spanish Drug Resistance Database Failing Tipranavir and Darunavir Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3018-3020.	3.2	8
326	Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 548-555.	3.0	51
327	Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1567-1569.	3.0	33
328	Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV. <i>Clinical Infectious Diseases</i> , 2010, 51, 1209-1216.	5.8	56
329	New therapeutic strategies for raltegravir. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 218-223.	3.0	11
330	European guideline for the management of hepatitis B and C virus infections, 2010. <i>International Journal of STD and AIDS</i> , 2010, 21, 669-678.	1.1	19
331	New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 379-382.	3.0	10
332	Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1493-1496.	3.0	40
333	Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2502-2504.	3.0	19
334	Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 320-326.	3.0	54
335	Long-term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-experienced Patients with Drug-resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials. <i>Clinical Infectious Diseases</i> , 2010, 50, 605-612.	5.8	196
336	Preemptive Erythropoietin Plus High Ribavirin Doses to Increase Rapid Virological Responses in HIV Patients Treated for Chronic Hepatitis C. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 419-424.	1.1	6
337	Renal toxicity associated with tenofovir use. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 545-559.	2.4	111
338	High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists—authors' response. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2057-2058.	3.0	0
339	Plasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1647-1649.	3.2	23
340	Low-Level Exposure to HIV Induces Virus-Specific T Cell Responses and Immune Activation in Exposed HIV-Seronegative Individuals. <i>Journal of Immunology</i> , 2010, 185, 982-989.	0.8	38
341	Population Pharmacokinetic Modeling of the Association between 63396C>T Pregnane X Receptor Polymorphism and Unboosted Atazanavir Clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 5242-5250.	3.2	66
342	High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1486-1492.	3.0	63

#	ARTICLE	IF	CITATIONS
343	Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 543-547.	3.0	51
344	Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. <i>Aids</i> , 2010, 24, 777-779.	2.2	11
345	Survival of HIV-infected patients with compensated liver cirrhosis. <i>Aids</i> , 2010, 24, 745-753.	2.2	32
346	Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. <i>Lancet, The</i> , 2010, 376, 367-387.	13.7	431
347	Prevalence of HTLV-1/2 Infections in Spain: A Cross-Sectional Hospital-Based Survey. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 861-864.	1.1	15
348	The Benefit of Simplification From Tipranavir/Ritonavir 500/200 bid to 500/100 bid Guided by Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 242-244.	2.0	0
349	Changes in Drug Resistance Patterns following the Introduction of HIV Type 1 Non-B Subtypes in Spain. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 967-972.	1.1	14
350	Liver Complications Have Reached a Plateau as Cause of Hospital Admission and Death in HIV Patients in Madrid. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 383-385.	1.1	9
351	Pharmacogenetics of tenofovir treatment. <i>Pharmacogenomics</i> , 2009, 10, 1675-1685.	1.3	56
352	Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 63, 1006-1010.	3.0	64
353	Injecting, Sexual Risk Behaviors and HIV Infection in Young Cocaine and Heroin Users in Spain. <i>European Addiction Research</i> , 2009, 15, 171-178.	2.4	19
354	Use of Different Inhibitory Quotients To Predict Early Virological Response to Tipranavir in Antiretroviral-Experienced Human Immunodeficiency Virus-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4153-4158.	3.2	6
355	Seroprevalence of HTLV-1/2 Infection among Native and Immigrant Pregnant Women in Spain. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 551-554.	1.1	30
356	Predictors of Kidney Tubular Dysfunction in HIV-Infected Patients Treated with Tenofovir: A Pharmacogenetic Study. <i>Clinical Infectious Diseases</i> , 2009, 48, e108-e116.	5.8	221
357	HIV protease inhibitors: recent clinical trials and recommendations on use. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 1615-1629.	1.8	38
358	Update on HIV viral-load assays: new technologies and testing in resource-limited settings. <i>Future Virology</i> , 2009, 4, 423-430.	1.8	6
359	Differences in Lopinavir Plasma Concentrations Comparing Kaletra® Film Coated Tablets and Soft Gelatine Capsules That Result in Various Lipid Abnormalities. <i>Drug Metabolism Letters</i> , 2009, 3, 67-69.	0.8	1
360	Seroreversion of Hepatitis C Virus (HCV) Antibodies in an HIV-Infected Patient despite Continuous HCV Replication. <i>Clinical Infectious Diseases</i> , 2009, 48, 1634-1635.	5.8	8

#	ARTICLE	IF	CITATIONS
361	Correlation between Human Immunodeficiency Virus Type 1 (HIV-1) RNA Measurements Obtained with Dried Blood Spots and Those Obtained with Plasma by Use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV Load Tests. <i>Journal of Clinical Microbiology</i> , 2009, 47, 1031-1036.	3.9	66
362	Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 398-410.	3.0	6
363	New Therapies for Hepatitis C Virus Infection. <i>Clinical Infectious Diseases</i> , 2009, 48, 313-320.	5.8	150
364	Rate and Timing of Hepatitis C Virus Relapse after a Successful Course of Pegylated Interferon plus Ribavirin in HIV-1-Infected and HIV-1-Uninfected Patients. <i>Clinical Infectious Diseases</i> , 2009, 49, 1397-1401.	5.8	35
365	Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. <i>Aids</i> , 2009, 23, 689-696.	2.2	250
366	Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. <i>Journal of Medical Virology</i> , 2009, 81, 763-767.	5.0	50
367	Level, phenotype and activation status of CD4+FoxP3+regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus. <i>Clinical and Experimental Immunology</i> , 2009, 155, 35-43.	2.6	46
368	Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. <i>Journal of Viral Hepatitis</i> , 2009, 16, 790-795.	2.0	35
369	Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. <i>Journal of Viral Hepatitis</i> , 2009, 16, 895-896.	2.0	49
370	Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. <i>HIV Medicine</i> , 2009, 10, 53-59.	2.2	28
371	Clinical Differences and Viral Diversity between Newly HIV Type 1-Diagnosed African and Non-African Patients in Spain (2005-2007). <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 37-44.	1.1	16
372	Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2009, 27, 28-32.	0.5	3
373	Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. <i>Journal of Clinical Virology</i> , 2009, 46, 173-175.	3.1	30
374	Raltegravir and Etravirine Are Active against HIV Type 1 Group O. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 225-227.	1.1	41
375	Short Communication: Transmission of Hepatitis B Viruses with Lamivudine Resistance Mutations in Newly Diagnosed HIV Individuals. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 1273-1276.	1.1	295
376	The role of injection versus socioeconomic factors in hepatitis A virus infection among young heroin users: Implications for vaccination policies. <i>Vaccine</i> , 2009, 27, 2674-2679.	3.8	3
377	648 DIFFERENCES IN ANTIVIRAL ACTIVITY AND TOLERABILITY BETWEEN PEGYLATED INTERFERON ALPHA 2A AND 2B IN HIV INFECTED PATIENTS WITH CHRONIC HEPATITIS C. <i>Journal of Hepatology</i> , 2009, 50, S238-S239.	3.7	2
378	When and how to use maraviroc in HIV-infected patients. <i>Aids</i> , 2009, 23, 2377-2385.	2.2	33

#	ARTICLE	IF	CITATIONS
379	Hepatitis B in HIV patients: what is the current treatment and what are the challenges?. Journal of HIV Therapy, 2009, 14, 13-8.	0.6	12
380	Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome. Journal of Viral Hepatitis, 2008, 15, 165-172.	2.0	94
381	Management of hepatitis B virus co-infection on and off antiretroviral therapy. Current HIV/AIDS Reports, 2008, 5, 86-93.	3.1	9
382	Genetic characterization of complex inter-recombinant HIV-1 strains circulating in Spain and reliability of distinct rapid subtyping tools. Journal of Medical Virology, 2008, 80, 383-391.	5.0	17
383	Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8 ⁺ T cells. European Journal of Immunology, 2008, 38, 1548-1558.	2.9	14
384	Emerging drugs for hepatitis C. Expert Opinion on Emerging Drugs, 2008, 13, 1-19.	2.4	41
385	European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Medicine, 2008, 9, 82-88.	2.2	222
386	Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. Journal of Viral Hepatitis, 2008, 15, 363-369.	2.0	24
387	Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. Journal of Viral Hepatitis, 2008, 15, 427-433.	2.0	87
388	Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. Journal of Viral Hepatitis, 2008, 15, 710-715.	2.0	15
389	Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection. New England Journal of Medicine, 2008, 359, 339-354.	27.0	699
390	Hepatitis B vaccination: An unmet challenge in the era of harm reduction programs. Journal of Substance Abuse Treatment, 2008, 34, 398-406.	2.8	12
391	Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. Journal of Hepatology, 2008, 49, 323-328.	3.7	40
392	Short Communication:HIV Rebound after Discontinuation of Antiretroviral Therapy Increases and Expands HIV-Specific CD8+Responses But Has No Impact on Its Functionality. AIDS Research and Human Retroviruses, 2008, 24, 1197-1201.	1.1	6
393	<i>Short Communication:</i> Association between Tipranavir Plasma Levels and Virological Response in HIV-Infected Patients. AIDS Research and Human Retroviruses, 2008, 24, 389-391.	1.1	3
394	Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection. New England Journal of Medicine, 2008, 359, 355-365.	27.0	498
395	Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. Journal of Antimicrobial Chemotherapy, 2008, 62, 1365-1373.	3.0	64
396	Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. Journal of Antimicrobial Chemotherapy, 2008, 61, 694-698.	3.0	53

#	ARTICLE	IF	CITATIONS
397	Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 699-704.	3.0	87
398	Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 626-627.	3.0	18
399	Changing Patterns in HIV Reverse Transcriptase Resistance Mutations after Availability of Tenofovir. <i>Clinical Infectious Diseases</i> , 2008, 46, 1782-1785.	5.8	19
400	HIV-1 Infection in Persistently HIV-1-Seronegative Individuals: More Reasons for HIV RNA Screening. <i>Clinical Infectious Diseases</i> , 2008, 46, 785-785.	5.8	6
401	Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1-4.	3.0	249
402	Prevalence of and Risk Factors for Hepatitis B Virus Infection among Street-Recruited Young Injection and Non-Injection Heroin Users in Barcelona, Madrid and Seville. <i>European Addiction Research</i> , 2008, 14, 116-124.	2.4	16
403	Autoimmune hepatitis induced by pegylated interferon in an HIV-infected patient with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1470-1472.	3.0	17
404	Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. <i>Aids</i> , 2008, 22, 611-616.	2.2	37
405	Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. <i>Aids</i> , 2008, 22, 1399-1410.	2.2	149
406	A low antiretroviral activity of the antihepatitis B drug entecavir may be enough to select for M184V in HIV-1. <i>Aids</i> , 2008, 22, 911-912.	2.2	12
407	Upper Gastrointestinal Bleeding May Unmask Didanosine-Associated Portal Hepatopathy in HIV/HCV Co-infected Patients. <i>HIV Clinical Trials</i> , 2008, 9, 440-444.	2.0	13
408	Statements from the 15th International Symposium on HIV and Emerging Infectious Diseases (ISHEID), Toulon, France, May 28-30, 2008. <i>HIV Clinical Trials</i> , 2008, 9, 348-365.	2.0	1
409	No Major Differences in the Functional Profile of HIV Gag and Nef-Specific CD8 ⁺ Responses between Long-Term Nonprogressors and Typical Progressors. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 1185-1195.	1.1	13
410	Switch from Ritonavir-Boosted to Unboosted Atazanavir Guided by Therapeutic Drug Monitoring. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 821-825.	1.1	39
411	Profile of Patients Triply Infected with HIV and the Hepatitis B and C Viruses in the HAART Era. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 679-683.	1.1	29
412	Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 816-822.	3.0	39
413	Hepatitis B virus escape mutants induced by antiviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 61, 766-768.	3.0	115
414	Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1174-1180.	3.0	78

#	ARTICLE	IF	CITATIONS
415	Performance of Three Commercial Viral Load Assays, Versant Human Immunodeficiency Virus Type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, Testing HIV-1 Non-B Subtypes and Recombinant Variants. <i>Journal of Clinical Microbiology</i> , 2008, 46, 2918-2923.	3.9	56
416	Editorial Commentary: Risks and Benefits of Using Antiretroviral Therapy in HIV-Infected Patients with Chronic Hepatitis B in Developing Regions. <i>Clinical Infectious Diseases</i> , 2008, 47, 1486-1489.	5.8	17
417	Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus in the Strategic Management of Antiretroviral Therapy (SMART) Study. <i>Clinical Infectious Diseases</i> , 2008, 47, 1468-1475.	5.8	53
418	Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes. <i>Journal of Clinical Microbiology</i> , 2008, 46, 887-891.	3.9	98
419	Management of Chronic Hepatitis C Virus Infection in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2008, 47, 94-101.	5.8	36
420	Reliability of Rapid Subtyping Tools Compared to That of Phylogenetic Analysis for Characterization of Human Immunodeficiency Virus Type 1 Non-B Subtypes and Recombinant Forms. <i>Journal of Clinical Microbiology</i> , 2008, 46, 3896-3899.	3.9	22
421	Increase of Non-B Subtypes and Recombinants Among Newly Diagnosed HIV-1 Native Spaniards and Immigrants in Spain. <i>Current HIV Research</i> , 2008, 6, 327-334.	0.5	58
422	Spontaneous Viral Clearance, Viral Load, and Genotype Distribution of Hepatitis C Virus (HCV) in HIV-Infected Patients with Anti-HCV Antibodies in Europe. <i>Journal of Infectious Diseases</i> , 2008, 198, 1337-1344.	4.0	145
423	Hepatitis C Virus Coinfection Does Not Affect CD4 Restoration in HIV-Infected Patients after Initiation of Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 935-940.	1.1	20
424	Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. <i>Aids</i> , 2008, 22, 2395-2398.	2.2	30
425	Initial spontaneous clearance and re-infection with a distinct hepatitis C virus genotype leading to chronic hepatitis C in an HIV+ intravenous drug user. <i>Aids</i> , 2008, 22, 318.	2.2	3
426	Impact of antiretroviral therapy on chemokine (C-C motif) receptor 5 expression in HIV patients followed for over 2 years. <i>Aids</i> , 2008, 22, 1371-1374.	2.2	2
427	Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance. <i>Aids</i> , 2008, 22, 311-313.	2.2	8
428	Optimal use of maraviroc in clinical practice. <i>Aids</i> , 2008, 22, 2231-2240.	2.2	33
429	Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. <i>Aids</i> , 2008, 22, 2535-2537.	2.2	36
430	Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. <i>Aids</i> , 2008, 22, 15-21.	2.2	57
431	Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain. <i>Blood Coagulation and Fibrinolysis</i> , 2008, 19, 333-340.	1.0	17
432	Low Rate of Adverse Hepatic Events Associated with Fosamprenavir/Ritonavir-Based Antiretroviral Regimens. <i>HIV Clinical Trials</i> , 2008, 9, 309-313.	2.0	10

#	ARTICLE	IF	CITATIONS
433	Antiretroviral drugs and liver injury. <i>Aids</i> , 2008, 22, 1-13.	2.2	163
434	Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. <i>Aids</i> , 2008, 22, 367-376.	2.2	43
435	Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfecting patients receiving lamivudine as part of antiretroviral therapy. <i>Aids</i> , 2008, 22, 1779-1787.	2.2	47
436	Efficacy and Safety of a Once Daily Regimen with Efavirenz, Lamivudine, and Didanosine, with and without Food, as Initial Therapy for HIV Infection: The ELADI Study. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1237-1241.	1.1	13
437	Short Communication: Dynamics of Drug-Resistant HIV-1 in Plasma and Peripheral Blood Cells in Patients during and after Enfuvirtide Therapy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1078-1082.	1.1	8
438	Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 1411-1413.	3.0	9
439	Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 200-205.	3.0	70
440	Amino Acid Conservation in the gp41 Transmembrane Protein and Natural Polymorphisms Associated with Enfuvirtide Resistance across HIV-1 Variants. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1067-1074.	1.1	13
441	Changing Rates and Patterns of Drug Resistance Mutations in Antiretroviral-Experienced HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 879-885.	1.1	35
442	Escape Mutations in HIV Infection and its Impact on CD8+ T Cell Responses. <i>Current Molecular Medicine</i> , 2007, 7, 446-458.	1.3	11
443	Influence of Human T Cell Lymphotropic Virus Type 2 Coinfection on Virological and Immunological Parameters in HIV Type 1-Infected Patients. <i>Clinical Infectious Diseases</i> , 2007, 44, 105-110.	5.8	16
444	Is natural conception a valid option for HIV-serodiscordant couples?. <i>Human Reproduction</i> , 2007, 22, 2353-2358.	0.9	72
445	Drug Interactions of Tipranavir, a New HIV Protease Inhibitor. <i>Drug Metabolism Letters</i> , 2007, 1, 81-84.	0.8	10
446	Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. <i>Aids</i> , 2007, 21, 583-588.	2.2	24
447	Care of patients coinfecting with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. <i>Aids</i> , 2007, 21, 1073-1089.	2.2	295
448	Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. <i>Aids</i> , 2007, 21, 41-46.	2.2	127
449	Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 839-850.	1.8	19
450	Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 972-982.	1.1	183

#	ARTICLE	IF	CITATIONS
451	Impact of Ethnicity and HIV Type 1 Subtype on Response to First-Line Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 891-894.	1.1	16
452	Liver Fibrosis Stage and HCV Genotype Distribution in HIV/HCV Coinfected Patients with Persistently Normal Transaminases. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 801-804.	1.1	20
453	Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 1409-1410.	3.0	31
454	Treatment of Chronic Hepatitis B or C in HIV-Infected Patients with Dual Viral Hepatitis. <i>Journal of Infectious Diseases</i> , 2007, 195, 1181-1183.	4.0	42
455	Human T Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis in an HIV-Positive Patient Coinfected with Human T Lymphotropic Virus Type 2 Following Initiation of Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2007, 45, e118-e120.	5.8	17
456	Quantitative Detection of Plasma Human Immunodeficiency Virus Type 2 Subtype A RNA by the Nuclisens EasyQ Assay (Version 1.1). <i>Journal of Clinical Microbiology</i> , 2007, 45, 88-92.	3.9	24
457	Telbivudine: a new option for the treatment of chronic hepatitis B. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 751-761.	3.1	35
458	CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 1141-1147.	3.0	4
459	Hepatotoxicity of Antiretroviral Drugs Is Reduced after Successful Treatment of Chronic Hepatitis C in HIV-Infected Patients. <i>Journal of Infectious Diseases</i> , 2007, 196, 670-676.	4.0	157
460	Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 885-888.	3.0	54
461	Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 698-704.	3.0	76
462	Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 405-410.	3.0	24
463	Prevalence of HIV infection among young adult injecting and non-injecting heroin users in Spain in the era of harm reduction programmes: gender differences and other related factors. <i>Epidemiology and Infection</i> , 2007, 135, 592-603.	2.1	21
464	Management and therapy of chronic hepatitis C in HIV. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 482-488.	3.8	1
465	Measurement of Ribavirin Plasma Concentrations by High-performance Liquid Chromatography Using a Novel Solid-phase Extraction Method in Patients Treated for Chronic Hepatitis C. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 802-806.	2.0	28
466	Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use. <i>Aids</i> , 2007, 21, 1487-1490.	2.2	42
467	Lack of anti-HIV activity of entecavir in an HIV patient coinfecting with hepatitis B and delta viruses. <i>Aids</i> , 2007, 21, 2253-2254.	2.2	6
468	Prevalence and therapeutic significance of anti-interferon antibodies in hepatitis C virus/HIV-co-infected patients. <i>Aids</i> , 2007, 21, 652-653.	2.2	2

#	ARTICLE	IF	CITATIONS
469	Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. <i>Aids</i> , 2007, 21, 2521-2527.	2.2	35
470	Outbreak of Syphilis, but Not of Acute Hepatitis C, Among HIV-Infected Homosexual Men in Madrid. <i>HIV Clinical Trials</i> , 2007, 8, 98-101.	2.0	20
471	Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide. <i>Journal of Clinical Virology</i> , 2007, 38, 176-180.	3.1	24
472	Poor validity of self-reported HBV vaccination among young heroin users in Spain supports the policy "ask, draw a blood sample, vaccinate and try to schedule another visit". <i>Journal of Clinical Virology</i> , 2007, 38, 87-90.	3.1	13
473	Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 679-688.	1.8	66
474	Short Communication: Hospital-Based Surveillance for HTLV-1/2 Infections in Spain. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1075-1077.	1.1	7
475	Value of the HLA-B*5701 Allele to Predict Abacavir Hypersensitivity in Spaniards. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1374-1376.	1.1	26
476	Introduction of Non-B Subtypes among Spaniards Newly Diagnosed with HIV Type 1 in the Canary Islands. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 498-502.	1.1	20
477	Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. <i>European Journal of Immunology</i> , 2007, 37, 501-515.	2.9	32
478	Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4+ and CD8+ T-cell responses to hepatitis C virus. <i>Journal of Medical Virology</i> , 2007, 79, 503-510.	5.0	26
479	Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. <i>Journal of Medical Virology</i> , 2007, 79, 1040-1046.	5.0	43
480	Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. <i>Infection, Genetics and Evolution</i> , 2007, 7, 382-390.	2.3	30
481	Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: Implications for HCV therapy in HCV/HIV-coinfected patients. <i>Journal of Infection</i> , 2007, 54, 173-179.	3.3	32
482	Hydroxyurea exerts an anti-proliferative effect on T cells but has no direct impact on cellular activation. <i>Clinical and Experimental Immunology</i> , 2007, 149, 171-177.	2.6	12
483	Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. <i>Journal of Viral Hepatitis</i> , 2007, 14, 387-391.	2.0	35
484	Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2007, 14, 392-395.	2.0	15
485	Evaluation of performance across the dynamic range of the Abbott RealTime [®] HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. <i>Journal of Virological Methods</i> , 2007, 141, 49-57.	2.1	49
486	Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 1171-1181.	4.1	25

#	ARTICLE	IF	CITATIONS
487	Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression. <i>Virus Genes</i> , 2007, 34, 111-116.	1.6	17
488	Update on the treatment of chronic hepatitis C in HIV-infected patients. <i>AIDS Reviews</i> , 2007, 9, 99-113.	1.0	10
489	¿Se debería recomendar el cribado de la infección por el virus linfotrópico humano de células T de tipo 1 en las mujeres embarazadas?. <i>Progresos En Obstetricia Y Ginecología</i> , 2006, 49, 523-525.	0.0	1
490	HTLV infection among young injection and non-injection heroin users in Spain: Prevalence and correlates. <i>Journal of Clinical Virology</i> , 2006, 35, 244-249.	3.1	29
491	Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. <i>Journal of Clinical Virology</i> , 2006, 36, 264-271.	3.1	55
492	Treatment of chronic hepatitis C in HIV-positive individuals: Selection of candidates. <i>Journal of Hepatology</i> , 2006, 44, S44-S48.	3.7	22
493	Standard of Care for HCV/HIV-Coinfected Patients. <i>Journal of Chemotherapy</i> , 2006, 18, 21-26.	1.5	0
494	Chronic Hepatitis C in HIV-Infected Patients: Those Who More Need Therapy are Those Who Respond Less. <i>Infectious Disorders - Drug Targets</i> , 2006, 6, 57-68.	0.8	1
495	Performance of Six Different Ritonavir-Boosted Protease Inhibitor-Based Regimens in Heavily Antiretroviral-Experienced HIV-Infected Patients. <i>HIV Clinical Trials</i> , 2006, 7, 163-171.	2.0	26
496	Successful rescue therapy with darunavir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors. <i>Aids</i> , 2006, 20, 1558-1560.	2.2	20
497	Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. <i>Aids</i> , 2006, 20, 1951-1954.	2.2	64
498	Confronting chronic hepatitis B virus infection in HIV: new diagnostic tools and more weapons. <i>Aids</i> , 2006, 20, 451-453.	2.2	10
499	HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors. <i>Aids</i> , 2006, 20, 1359-1367.	2.2	71
500	Mutations affecting the replication capacity of the hepatitis B virus. <i>Journal of Viral Hepatitis</i> , 2006, 13, 427-434.	2.0	109
501	Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002. <i>Journal of Viral Hepatitis</i> , 2006, 13, 851-857.	2.0	13
502	Overview of the pharmacogenetics of HIV therapy. <i>Pharmacogenomics Journal</i> , 2006, 6, 234-245.	2.0	55
503	Serum endostatin and bFGF as predictive factors in advanced breast cancer patients treated with letrozole. <i>Clinical and Translational Oncology</i> , 2006, 8, 193-199.	2.4	15
504	Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain. <i>Journal of Medical Virology</i> , 2006, 78, 1599-1608.	5.0	33

#	ARTICLE	IF	CITATIONS
505	Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. <i>Aids</i> , 2006, 20, 1071-1074.	2.2	29
506	Variability in the P6gag domains of HIV-1 involved in viral budding. <i>Aids</i> , 2006, 20, 624-627.	2.2	9
507	Effectiveness and Safety of Abacavir, Lamivudine, and Zidovudine in Antiretroviral Therapy-Naive HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 41, 154-159.	2.1	18
508	Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis B Extensively Exposed to Antiretroviral Therapy with Anti-HBV Activity. <i>HIV Clinical Trials</i> , 2006, 7, 246-250.	2.0	26
509	Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART. <i>Aids</i> , 2006, 20, 1460-1462.	2.2	23
510	Limited but increasing use of treatment for hepatitis C across Europe in patients coinfectd with HIV and hepatitis C. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 1092-1097.	1.5	15
511	Plasma Levels of Atazanavir and the Risk of Hyperbilirubinemia Are Predicted by the 3435C->T Polymorphism at the Multidrug Resistance Gene 1. <i>Clinical Infectious Diseases</i> , 2006, 42, 291-295.	5.8	116
512	Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 806-809.	3.0	33
513	Can the Level of Immunosuppression in Human Immunodeficiency Virus-Infected Patients Affect the Reliability of Human T-Cell Lymphotropic Virus Type 2 Serological Diagnosis?. <i>Vaccine Journal</i> , 2006, 13, 160-161.	3.1	7
514	HIV entry inhibitors: mechanisms of action and resistance pathways. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 619-627.	3.0	156
515	Coinfection with Hepatitis C Virus Increases Lymphocyte Apoptosis in HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2006, 43, 1209-1212.	5.8	36
516	Chemoprophylaxis with Tenofovir Disoproxil Fumarate Provided Partial Protection against Infection with Simian Human Immunodeficiency Virus in Macaques Given Multiple Virus Challenges. <i>Journal of Infectious Diseases</i> , 2006, 194, 904-911.	4.0	185
517	Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 694-701.	3.2	78
518	Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes. <i>Journal of Epidemiology and Community Health</i> , 2006, 60, 537-542.	3.7	32
519	Management of chronic hepatitis B and C in HIV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 815-818.	3.0	78
520	Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 709-713.	3.0	79
521	Predictors of Liver Fibrosis in HIV-Infected Patients with Chronic Hepatitis C Virus (HCV) Infection: Assessment Using Transient Elastometry and the Role of HCV Genotype 3. <i>Clinical Infectious Diseases</i> , 2006, 42, 1032-1039.	5.8	51
522	New paradigms in the management of HIV and hepatitis C virus coinfection. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 550-560.	3.1	15

#	ARTICLE	IF	CITATIONS
523	Characteristics and Prospects for Hepatitis C Therapy of an HIV-HCV Coinfected Population Followed at a Reference HIV Center. <i>HIV Clinical Trials</i> , 2005, 6, 329-336.	2.0	23
524	Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. <i>Aids</i> , 2005, 19, 569-575.	2.2	75
525	Reductions in Stavudine Dose Might Ameliorate Mitochondrial-Associated Complications Without Compromising Antiviral Activity. <i>HIV Clinical Trials</i> , 2005, 6, 197-202.	2.0	28
526	HIV-1 subtypes in Spain: a retrospective analysis from 1995 to 2003. <i>HIV Medicine</i> , 2005, 6, 313-320.	2.2	46
527	Clinical benefit of interventions driven by therapeutic drug monitoring. <i>HIV Medicine</i> , 2005, 6, 360-365.	2.2	32
528	Addressing current challenges in haemophilia care: consensus recommendations of a European Interdisciplinary Working Group. <i>Haemophilia</i> , 2005, 11, 433-437.	2.1	9
529	Natural history of Hymenoptera venom allergy in Eastern Spain. <i>Clinical and Experimental Allergy</i> , 2005, 35, 179-185.	2.9	29
530	Multicenter evaluation of the NucliSens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma. <i>Journal of Virological Methods</i> , 2005, 127, 54-59.	2.1	42
531	Heterogeneous nature of HIV-1 recombinants spreading in Spain. <i>Journal of Medical Virology</i> , 2005, 75, 374-380.	5.0	23
532	Relationship between drug resistance mutations, plasma viremia, and CD4+T-cell counts in patients with chronic HIV infection. <i>Journal of Medical Virology</i> , 2005, 76, 1-6.	5.0	8
533	Infection with human T lymphotropic virus type I in organ transplant donors and recipients in Spain. <i>Journal of Medical Virology</i> , 2005, 76, 268-270.	5.0	27
534	Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , 2005, 77, 23-28.	5.0	23
535	Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , 2005, 77, 460-464.	5.0	21
536	Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration. <i>PLoS Medicine</i> , 2005, 2, e112.	8.4	262
537	Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3997-4008.	3.2	42
538	Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors and Prevalence of HIV Type 1 Non-B Subtypes Are Increasing among Persons with Recent Infection in Spain. <i>Clinical Infectious Diseases</i> , 2005, 41, 1350-1354.	5.8	53
539	Antiretroviral Recommendations May Influence the Rate of Transmission of Drug-Resistant HIV Type 1. <i>Clinical Infectious Diseases</i> , 2005, 41, 227-232.	5.8	31
540	Viral Response to Antiretroviral Therapy in a Patient Coinfected with HIV Type 1 and Type 2. <i>Clinical Infectious Diseases</i> , 2005, 41, e19-e21.	5.8	19

#	ARTICLE	IF	CITATIONS
541	Superiority of Protease Inhibitors over Nonnucleoside Reverse-Transcriptase Inhibitors when Highly Active Antiretroviral Therapy Is Resumed after Treatment Interruption. <i>Clinical Infectious Diseases</i> , 2005, 41, 897-900.	5.8	11
542	Prevalence of Drug-Resistant HIV-1 Variants in Untreated Individuals in Europe: Implications for Clinical Management. <i>Journal of Infectious Diseases</i> , 2005, 192, 958-966.	4.0	385
543	Failure of Hepatitis C Therapy in HIV-Coinfected Drug Users Is Not Due to a Shift in Hepatitis C Virus Genotype. <i>Journal of Infectious Diseases</i> , 2005, 192, 1245-1248.	4.0	8
544	Impact of Human Immunodeficiency Virus Type 1 (HIV-1) Genetic Diversity on Performance of Four Commercial Viral Load Assays: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. <i>Journal of Clinical Microbiology</i> , 2005, 43, 3860-3868.	3.9	103
545	Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. <i>Clinical Infectious Diseases</i> , 2005, 41, 1772-1782.	5.8	197
546	CD4+T Cell Recovery beyond the First Year of Complete Suppression of Viral Replication during Highly Active Antiretroviral Therapy Is Not Influenced by CD8+T Cell Activation. <i>Journal of Infectious Diseases</i> , 2005, 192, 2142-2146.	4.0	20
547	Atazanavir: The Advent of a New Generation of More Convenient Protease Inhibitors. <i>HIV Clinical Trials</i> , 2005, 6, 50-61.	2.0	5
548	Hepatic and Renal Safety Profile of Tenofovir in HIV-Infected Patients with Hepatitis C, Including Patients on Interferon Plus Ribavirin. <i>HIV Clinical Trials</i> , 2005, 6, 278-280.	2.0	15
549	Risk of selecting K65R in antiretroviral-naïve HIV-infected individuals with chronic hepatitis B treated with adefovir. <i>Aids</i> , 2005, 19, 2036-2038.	2.2	46
550	Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. <i>Aids</i> , 2005, 19, 2117-2125.	2.2	109
551	Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients. <i>Aids</i> , 2005, 19, 621-623.	2.2	8
552	Hepatitis C Viremia in HIV/HCV-Coinfected Patients: Lower Levels in Presence of Chronic Hepatitis B. <i>HIV Clinical Trials</i> , 2005, 6, 103-106.	2.0	7
553	Management of patients co-infected with hepatitis B virus and HIV. <i>Lancet Infectious Diseases</i> , The, 2005, 5, 374-382.	9.1	63
554	Complications in treating chronic hepatitis B in patients with HIV. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 2831-2842.	1.8	2
555	Influence of 516G>T Polymorphisms at the Gene Encoding the CYP450-2B6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected Subjects. <i>Clinical Infectious Diseases</i> , 2005, 40, 1358-1361.	5.8	176
556	Influence of Hepatitis C Virus Infection on HIV-1 Disease Progression and Response to Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2005, 192, 992-1002.	4.0	362
557	Risks and benefits of antiretroviral therapy in HIV-HCV co-infected patients. <i>Journal of Hepatology</i> , 2005, 42, 290-292.	3.7	12
558	Influence of HTLV-2 infection on hepatitis C virus replication in HIV-positive patients. <i>Journal of Clinical Virology</i> , 2005, 32, 338-339.	3.1	6

#	ARTICLE	IF	CITATIONS
559	Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain. Journal of Clinical Virology, 2005, 33, 65-70.	3.1	15
560	Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. Journal of Clinical Virology, 2005, 34, 295-301.	3.1	55
561	Hepatotoxicity of Antiretrovirals. Drug Safety, 2005, 28, 53-66.	3.2	91
562	Phage Display Selection of HIV Specific Conserved Mimotopes With IgG from Long-term Non-progressors. Retrovirology, 2005, 2, P29.	2.0	0
563	Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. Aids, 2005, 19, 221-40.	2.2	49
564	Prediction of Virological Response to Lopinavir/Ritonavir Using the Genotypic Inhibitory Quotient. AIDS Research and Human Retroviruses, 2004, 20, 275-278.	1.1	59
565	CD38 Expression on CD8 T Lymphocytes as a Marker of Residual Virus Replication in Chronically HIV-Infected Patients Receiving Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2004, 20, 227-233.	1.1	80
566	Are Fusion Inhibitors Active against All HIV Variants?. AIDS Research and Human Retroviruses, 2004, 20, 347-348.	1.1	51
567	Failure to Detect Human Immunodeficiency Virus Type 1 Superinfection in 28 HIV-Seroconcordant Individuals with High Risk of Reexposure to the Virus. AIDS Research and Human Retroviruses, 2004, 20, 1026-1031.	1.1	32
568	Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C: A European Collaborative Study. Clinical Infectious Diseases, 2004, 38, 128-133.	5.8	291
569	Evidence for Differences in the Sexual Transmission Efficiency of HIV Strains with Distinct Drug Resistance Genotypes. Clinical Infectious Diseases, 2004, 39, 1231-1238.	5.8	32
570	Different Viral Rebound following Discontinuation of Antiretroviral Therapy in Cases of Infection with Viruses Carrying L74V or Thymidine-Associated Mutations. Journal of Clinical Microbiology, 2004, 42, 862-866.	3.9	2
571	Analyzing Sleep Abnormalities in HIV-Infected Patients Treated with Efavirenz. Clinical Infectious Diseases, 2004, 38, 430-432.	5.8	128
572	Modifications in SENV DNA Detection and/or SENV Subtype Determination over a Prospective Follow-Up in a Cohort of HIV-Positive Patients: Is This a Moving Target?. Intervirology, 2004, 47, 350-354.	2.8	3
573	Impact of Chronic Hepatitis C on HIV-1 Disease Progression. HIV Clinical Trials, 2004, 5, 125-131.	2.0	44
574	How effective is HAART in HCV and HIV coinfection?. Aids, 2004, 18, 2081-2084.	2.2	6
575	Hepatocellular carcinoma in HIV-infected patients. Aids, 2004, 18, 2285-2293.	2.2	213
576	HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. Aids, 2004, 18, 495-502.	2.2	39

#	ARTICLE	IF	CITATIONS
577	Short Communication: Liver Toxicity of Lopinavir-Containing Regimens in HIV-Infected Patients with or without Hepatitis C Coinfection. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 698-700.	1.1	44
578	Hepatitis C Virus (HCV) Relapses after Anti-HCV Therapy Are More Frequent in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 351-353.	1.1	42
579	Changes in Mitochondrial DNA Copy Number in Blood Cells from HIV-Infected Patients Undergoing Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 271-273.	1.1	41
580	Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. <i>Journal of Virological Methods</i> , 2004, 121, 115-118.	2.1	25
581	Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. <i>Journal of Viral Hepatitis</i> , 2004, 11, 2-17.	2.0	65
582	Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-1 infected patients experiencing prolonged virologic failure. <i>Journal of Medical Virology</i> , 2004, 74, 21-28.	5.0	64
583	Prevalence of HIV-1 non-B subtypes, syphilis, HTLV, and hepatitis B and C viruses among immigrant sex workers in Madrid, Spain. <i>Journal of Medical Virology</i> , 2004, 74, 521-527.	5.0	47
584	Management of Chronic Hepatitis C in Patients Co-Infected with HIV. <i>Drug Safety</i> , 2004, 27, 7-24.	3.2	13
585	Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. <i>Journal of Clinical Virology</i> , 2004, 31, 215-220.	3.1	56
586	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. <i>Lancet, The</i> , 2004, 364, 51-62.	13.7	303
587	Prevalence of drug resistance genotypes causing broad cross-resistance to nucleos(t)ide analogues. <i>Aids</i> , 2004, 18, 689-690.	2.2	4
588	Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea. <i>Aids</i> , 2004, 18, 1251-1261.	2.2	11
589	Reply to Bruno et al.. <i>Aids</i> , 2004, 18, 2102-2103.	2.2	0
590	New Hopes for HIV and HCV Coinfection in 2004. <i>HIV Clinical Trials</i> , 2004, 5, 232-251.	2.0	9
591	Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations. <i>Aids</i> , 2004, 18, 2091-2094.	2.2	16
592	Tenofovir-related nephrotoxicity in HIV-infected patients. <i>Aids</i> , 2004, 18, 960-963.	2.2	96
593	Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide. <i>Aids</i> , 2004, 18, 1137-1146.	2.2	64
594	Predictors of selection of K65R. <i>Aids</i> , 2004, 18, 2094-2096.	2.2	36

#	ARTICLE	IF	CITATIONS
595	Care of patients with hepatitis C and HIV co-infection. <i>Aids</i> , 2004, 18, 1-12.	2.2	194
596	Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. <i>Aids</i> , 2004, 18, 1109-1116.	2.2	93
597	Predictors of Virological Response to Atazanavir in Protease Inhibitor-Experienced Patients. <i>HIV Clinical Trials</i> , 2004, 5, 201-205.	2.0	66
598	Resistance to HIV Protease Inhibitors: Mechanisms and Clinical Consequences. <i>Current Drug Metabolism</i> , 2004, 5, 321-328.	1.2	29
599	Performance of drug resistance assays in testing HIV-1 non-B subtypes. <i>Clinical Microbiology and Infection</i> , 2003, 9, 323-326.	6.0	12
600	Human immunodeficiency virus type 1 recombinant B/G subtypes circulating in Coimbra, Portugal. <i>Clinical Microbiology and Infection</i> , 2003, 9, 422-425.	6.0	12
601	Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon α -2b Plus Ribavirin. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1083-1089.	1.1	25
602	Distribution of Hepatitis B Virus Genotypes in HIV-Infected Patients with Chronic Hepatitis B: Therapeutic Implications. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 657-659.	1.1	34
603	Short Communication: Interactions between Nevirapine Plasma Levels, Chronic Hepatitis C, and the Development of Liver Toxicity in HIV-Infected Patients. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 187-188.	1.1	31
604	Indinavir Plasma Concentrations and Resistance Mutations in Patients Experiencing Early Virological Failure. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 457-459.	1.1	13
605	Changes in the Human Immunodeficiency Virus p7-p1-p6 gag Gene in Drug-Naive and Pretreated Patients. <i>Journal of Clinical Microbiology</i> , 2003, 41, 1245-1247.	3.9	33
606	Treatment of Chronic Hepatitis B in the Human Immunodeficiency Virus-Infected Patient: Present and Future. <i>Clinical Infectious Diseases</i> , 2003, 37, 1678-1685.	5.8	56
607	Impact of Hepatitis C Virus (HCV) on Morbidity and Mortality Rates among HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2003, 37, 460-461.	5.8	3
608	Rate, Causes, and Clinical Implications of Presenting with Low CD4+ Cell Counts in the Era of Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 363-368.	1.1	14
609	SENV Infection in HIV-Positive Patients: Prevalence, Subtype Characterization, and Impact on HIV Disease Progression. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 1079-1082.	1.1	7
610	Gynecomastia in HIV-Infected Patients Receiving Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 739-741.	1.1	12
611	Transmission of HIV Type 1 through Blood Transfusion from an Antibody-Negative/p24 Antigen-Negative Donor. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 447-448.	1.1	4
612	Role of Baseline Human Immunodeficiency Virus Genotype as a Predictor of Viral Response to Tenofovir in Heavily Pretreated Patients. <i>Journal of Clinical Microbiology</i> , 2003, 41, 4421-4423.	3.9	11

#	ARTICLE	IF	CITATIONS
613	First-Line Therapy and Mitochondrial Damage: Different Nucleosides, Different Findings. HIV Clinical Trials, 2003, 4, 11-19.	2.0	31
614	Pegylated IFN- α 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. Aids, 2003, 17, 1023-1028.	2.2	183
615	Hepatitis B Virus Infection Despite Receiving Lamivudine in One HIV-Infected Person. HIV Clinical Trials, 2003, 4, 77-78.	2.0	4
616	HIV-Positive Immigrants in the Canary Islands, Spain: Implications for Public Health in Europe. HIV Clinical Trials, 2003, 4, 184-192.	2.0	16
617	Replacement of Protease Inhibitors by Nevirapine or Efavirenz in Simplification and Rescue Interventions: Which Works Better?. HIV Clinical Trials, 2003, 4, 244-247.	2.0	3
618	Combination Antiretroviral Therapy and the Risk of Myocardial Infarction. New England Journal of Medicine, 2003, 349, 1993-2003.	27.0	1,560
619	Hydroxyurea plus Didanosine as Maintenance Therapy for HIV-Infected Patients on Long-Term Successful Highly Active Antiretroviral Therapy. HIV Clinical Trials, 2003, 4, 361-371.	2.0	16
620	Avascular Necrosis in HIV-Infected Patients Receiving Antiretroviral Treatment: Study of Seven Cases. HIV Clinical Trials, 2003, 4, 132-136.	2.0	21
621	Incidence of Liver Injury After Beginning Antiretroviral Therapy with Efavirenz or Nevirapine. HIV Clinical Trials, 2003, 4, 115-120.	2.0	106
622	Long-Term Outcome of HIV-Infected Patients with Multinucleoside-Resistant Genotypes. HIV Clinical Trials, 2003, 4, 372-381.	2.0	7
623	Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus Type I from a single donor. Transplantation, 2003, 75, 102-104.	1.0	116
624	Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations. Aids, 2003, 17, 442-444.	2.2	4
625	Low rate of HIV-1 codon 215 revertants in antiretroviral-experienced patients. Aids, 2003, 17, 919-921.	2.2	4
626	Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy. Aids, 2003, 17, 921-924.	2.2	18
627	Toxicidad mitocondrial de los antirretrovirales: diagnóstico y monitorización. Medicina Clínica, 2003, 121, 310-315.	0.6	5
628	HIV-1 Subtype J Recombinant Viruses in Spain. AIDS Research and Human Retroviruses, 2002, 18, 523-529.	1.1	10
629	Differences in Cellular Activation and Apoptosis in HIV-Infected Patients Receiving Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors. AIDS Research and Human Retroviruses, 2002, 18, 1379-1388.	1.1	34
630	Prevalence of the HIV Protease Mutation N88S Causing Hypersensitivity to Amprenavir. Clinical Infectious Diseases, 2002, 34, 1288-1289.	5.8	4

#	ARTICLE	IF	CITATIONS
631	Short Communication:Prevalence of G333D/E in Naive and Pretreated HIV-Infected Patients. AIDS Research and Human Retroviruses, 2002, 18, 857-860.	1.1	19
632	Hcv Chronic Hepatitis in Patients With Hiv: Clinical Management Issues. American Journal of Gastroenterology, 2002, 97, 1598-1606.	0.4	25
633	Rapid Assessment of Phenotypic Resistance to Protease Inhibitors in Human Immunodeficiency Virus Type 1 Group O. Journal of Clinical Microbiology, 2002, 40, 4313-4316.	3.9	4
634	Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. Sexually Transmitted Infections, 2002, 78, 255-260.	1.9	20
635	Genetic mechanisms of resistance to NRTI and NNRTI. HIV Clinical Trials, 2002, 3, 237-248.	2.0	32
636	Does an Increase in Nevirapine Plasma Levels Cause Complete Virologic Suppression in Patients Experiencing Early Virologic Failure?. HIV Clinical Trials, 2002, 3, 463-467.	2.0	9
637	High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. Aids, 2002, 16, 1163-1170.	2.2	61
638	Resistance to Antiretroviral Agents in Individuals with HIV-1 Non-B Subtypes. HIV Clinical Trials, 2002, 3, 403-411.	2.0	32
639	Rate of Virological Treatment Failure and Frequencies of Drug Resistance Genotypes among Human Immunodeficiency Virus-Positive Subjects on Antiretroviral Therapy in Spain. Journal of Clinical Microbiology, 2002, 40, 3865-3866.	3.9	30
640	Evaluation of the Abbott LCx Quantitative Assay for Measurement of Human Immunodeficiency Virus RNA in Plasma. Journal of Clinical Microbiology, 2002, 40, 1518-1521.	3.9	28
641	Liver Biopsy in HIV-Infected Patients with Chronic Hepatitis C: Pros and Cons. HIV Clinical Trials, 2002, 3, 351-353.	2.0	6
642	Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. Aids, 2002, 16, 245-249.	2.2	57
643	Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIVâ€“HCV International Panel. Aids, 2002, 16, 813-828.	2.2	280
644	Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. HIV Clinical Trials, 2002, 3, 249-257.	2.0	9
645	Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter. HIV Clinical Trials, 2002, 3, 9-16.	2.0	18
646	Salvage Treatment with Lopinavir/Ritonavir (Kaletra) in HIV-Infected Patients Failing All Current Antiretroviral Drug Families. HIV Clinical Trials, 2002, 3, 304-309.	2.0	40
647	SENC (Spanish efavirenz vs. nevirapine comparison) trial: A randomized, open-label study in HIV-infected naive individuals. HIV Clinical Trials, 2002, 3, 186-194.	2.0	58
648	Management of chronic viral hepatitis in HIV-infected patients: Spanish Consensus Conference. HIV Clinical Trials, 2002, 3, 99-114.	2.0	23

#	ARTICLE	IF	CITATIONS
649	Infection with Retroviruses Other Than HIV-1 in Spain: A Retrospective Analysis for HIV-2, HTLV-I, and/or HTLV-II. HIV Clinical Trials, 2002, 3, 397-402.	2.0	10
650	Cryptosporidiosis. New England Journal of Medicine, 2002, 347, 1287-1287.	27.0	38
651	Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors. International Journal of Antimicrobial Agents, 2002, 20, 438-443.	2.5	41
652	Treatment of chronic hepatitis C with pegylated interferon plus ribavirin in HIV-infected patients. Journal of Hepatology, 2002, 36, 107.	3.7	0
653	Efficacy and safety of combination therapy with interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. Journal of Hepatology, 2002, 36, 108.	3.7	0
654	Motivo de ingreso hospitalario en pacientes con infección por el virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad. Medicina Clínica, 2002, 119, 293-295.	0.6	3
655	A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. HIV Medicine, 2002, 3, 229-238.	2.2	12
656	Liver toxicity caused by nevirapine. Aids, 2002, 16, 290-291.	2.2	151
657	Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment. Aids, 2002, 16, 493-495.	2.2	15
658	Lipodystrophy body-shape changes in a patient undergoing zidovudine monotherapy. Aids, 2002, 16, 1087-1089.	2.2	9
659	Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. Aids, 2002, 16, 1423-1425.	2.2	31
660	Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. Aids, 2002, 16, 1830-1832.	2.2	26
661	Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. Aids, 2002, 16, 1959-1961.	2.2	51
662	Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. Aids, 2002, 16, 1964-1966.	2.2	31
663	Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. Aids, 2002, 16, 2079-2081.	2.2	48
664	Lack of "occult" hepatitis B virus infection in HIV-infected patients. Aids, 2002, 16, 2099-2101.	2.2	72
665	Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. Aids, 2002, 16, 2352-2354.	2.2	101
666	Genetic mechanisms of resistance to NRTI and NNRTI. HIV Clinical Trials, 2002, 3, 237-48.	2.0	15

#	ARTICLE	IF	CITATIONS
667	Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. HIV Clinical Trials, 2002, 3, 249-57.	2.0	4
668	Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. American Journal of Gastroenterology, 2001, 96, 179-183.	0.4	62
669	Response to Drs. Toyoda et al.. American Journal of Gastroenterology, 2001, 96, 3441-3442.	0.4	0
670	The effect of antiretroviral therapy on HTLV infection. Virus Research, 2001, 78, 93-100.	2.2	48
671	Prevalence and Genetic Heterogeneity of the Reverse Transcriptase T69S-S-X Insertion in Pretreated HIV-Infected Patients. Intervirology, 2001, 44, 339-343.	2.8	10
672	Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. Aids, 2001, 15, 1701-1706.	2.2	61
673	Role of Nonnucleosides in the Development of HAART-Related Lipid Disturbances. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 28, 496-498.	2.1	6
674	Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies. Clinical Microbiology and Infection, 2001, 7, 678-681.	6.0	16
675	Monitoring the response to antiretroviral therapy in HIV-1 group O infected patients using two new RT-PCR assays. Journal of Medical Virology, 2001, 64, 217-222.	5.0	10
676	Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors. Journal of Medical Virology, 2001, 63, 85-87.	5.0	17
677	Management of hepatitis C in HIV-infected persons. Antiviral Research, 2001, 52, 189-198.	4.1	28
678	Intensification of Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2001, 17, 499-506.	1.1	5
679	Comparative Performance of Three Viral Load Assays on Human Immunodeficiency Virus Type 1 (HIV-1) Isolates Representing Group M (Subtypes A to G) and Group O: LCx HIV RNA Quantitative, AMPLICOR HIV-1 MONITOR Version 1.5, and Quantiplex HIV-1 RNA Version 3.0. Journal of Clinical Microbiology, 2001, 39, 862-870.	3.9	54
680	Primary lymphoma of the central nervous system and HTLV-I infection. Haematologia, 2001, 31, 365-367.	0.3	12
681	Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. Aids, 2001, 15, 309-320.	2.2	169
682	Sequencing antiretroviral drugs. Aids, 2001, 15, 547-551.	2.2	13
683	Increasing Impact of Chronic Viral Hepatitis on Hospital Admissions and Mortality among HIV-Infected Patients. AIDS Research and Human Retroviruses, 2001, 17, 1467-1471.	1.1	197
684	Molecular Evidence of Homosexual Transmission of HIV Type 2 in Spain. AIDS Research and Human Retroviruses, 2001, 17, 417-422.	1.1	21

#	ARTICLE	IF	CITATIONS
685	Response to Drs. Toyoda et al.. American Journal of Gastroenterology, 2001, 96, 3441-3442.	0.4	1
686	Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. American Journal of Gastroenterology, 2001, 96, 179-183.	0.4	215
687	Prevalence of Human Immunodeficiency Virus Type 1 (HIV-1) Non-B Subtypes in Foreigners Living in Madrid, Spain, and Comparison of the Performances of the AMPLICOR HIV-1 MONITOR Version 1.0 and the New Automated Version 1.5. Journal of Clinical Microbiology, 2001, 39, 1850-1854.	3.9	34
688	Mortality Due to Chronic Viral Liver Disease among Patients Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases, 2001, 33, 1793-1795.	5.8	46
689	Naturally Occurring Sequence Polymorphisms within HIV Type 1 Group O Protease. AIDS Research and Human Retroviruses, 2001, 17, 1555-1561.	1.1	25
690	Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. Aids, 2001, 15, 1894-1896.	2.2	37
691	Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine. Aids, 2001, 15, 2469-2470.	2.2	4
692	Protease sequences from HIV-1 group M subtypes A??H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. Aids, 2000, 14, 1489-1495.	2.2	125
693	Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. Aids, 2000, 14, 2153-2157.	2.2	74
694	Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. Aids, 2000, 14, 383-386.	2.2	109
695	Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. Aids, 2000, 14, 913-919.	2.2	20
696	Human immunodeficiency virus type 2 (HIV-2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. , 2000, 61, 111-116.		89
697	Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. Journal of Viral Hepatitis, 2000, 7, 403-408.	2.0	34
698	Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO Journal, 2000, 19, 5752-5761.	7.8	100
699	Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. Aids, 2000, 14, 727-732.	2.2	53
700	Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. Aids, 2000, 14, 807-812.	2.2	143
701	Protease Gene Analysis of HIV Type 1 Non-B Subtypes in Spain. AIDS Research and Human Retroviruses, 2000, 16, 1395-1403.	1.1	30
702	Prevalence of HTLV infection in pregnant women in Spain. Sexually Transmitted Infections, 2000, 76, 366-370.	1.9	37

#	ARTICLE	IF	CITATIONS
703	Is there a role for indinavir twice-daily in clinical practice?. <i>Clinical Microbiology and Infection</i> , 2000, 6, 152-154.	6.0	1
704	Tolerability of Abacavir in the clinical setting. <i>Clinical Microbiology and Infection</i> , 2000, 6, 621-622.	6.0	0
705	Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy. <i>Virus Research</i> , 2000, 66, 13-26.	2.2	34
706	Carga viral y valores de linfocitos CD4+ en la era de la terapia antirretroviral altamente potente. <i>Medicina Clínica</i> , 2000, 115, 118.	0.6	2
707	Recombinant Human Immunodeficiency Viruses Type 1 Circulating in Spain. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 505-511.	1.1	29
708	Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 207.	2.2	4
709	Hepatitis C viraemia in HIV/HCV co-infected patients having immune restoration with highly active antiretroviral therapy. <i>Aids</i> , 2000, 14, 212.	2.2	61
710	Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure. <i>Aids</i> , 2000, 14, 1659-1660.	2.2	5
711	Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash?. <i>Aids</i> , 2000, 14, 1672-1673.	2.2	25
712	Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 2000, 14, 2409-2410.	2.2	8
713	Emergence of Drug Resistance Mutations in Human Immunodeficiency Virus Type 2-Infected Subjects Undergoing Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2000, 38, 1370-1374.	3.9	81
714	Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. <i>Journal of Medical Virology</i> , 2000, 61, 111-6.	5.0	32
715	Human Immunodeficiency Virus Type 2 Infection in Spain. <i>Intervirology</i> , 1999, 42, 37-42.	2.8	17
716	CCR5 genotype and HIV-1 infection in perinatally-exposed infants. <i>Journal of Infection</i> , 1999, 38, 9-11.	3.3	10
717	CCR5 Genotype and Human Immunodeficiency Virus Type 1 Infection in Perinatally Exposed Infants. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 389-391.	2.9	3
718	Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. <i>European Journal of Epidemiology</i> , 1999, 15, 1-4.	5.7	158
719	Human T-cell Leukemia/Lymphoma Virus Type II Infection in Spain. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 75-76.	2.9	5
720	Association Between Submaximal Suppression of HIV Replication and Use of Drug Combinations Without Protease Inhibitors. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 604-605.	2.9	0

#	ARTICLE	IF	CITATIONS
721	Diabetes Mellitus Associated with Protease Inhibitor Use. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 1999, 18, 675-677.	2.9	11
722	Human immunodeficiency viruses type 1 subtypes circulating in Spain. <i>Journal of Medical Virology</i> , 1999, 59, 189-193.	5.0	18
723	Hepatitis C and HIV infection: biological, clinical, and therapeutic implications. <i>Journal of Hepatology</i> , 1999, 31, 119-123.	3.7	61
724	Phylogeny of HIV Type 1 Group O Isolates Based on env Gene Sequences. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 769-773.	1.1	11
725	Higher antiviral activity of antiretroviral regimens including protease inhibitors. <i>Aids</i> , 1999, 13, 998.	2.2	8
726	Introduction of HIV drug-resistance testing in clinical practice. <i>Aids</i> , 1999, 13, 1007-1014.	2.2	62
727	Management of chronic hepatitis C in HIV-infected patients. <i>Aids</i> , 1999, 13, 539-546.	2.2	90
728	Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. <i>Aids</i> , 1999, 13, 1763-1769.	2.2	540
729	Incidence of rash and discontinuation of nevirapine using two different escalating initial doses. <i>Aids</i> , 1999, 13, 524.	2.2	26
730	Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy. <i>Aids</i> , 1999, 13, 525.	2.2	25
731	V3-loop and nef gene sequences of HIV-1 isolates from a hemophiliac cohort with long-term non-progressive infection. <i>Aids</i> , 1999, 13, 532.	2.2	5
732	Spanish consensus conference on drug resistance testing in clinical practice. <i>Aids</i> , 1999, 13, 1998.	2.2	15
733	What dual protease inhibitor combination for salvage therapies?. <i>Aids</i> , 1999, 13, 2180.	2.2	9
734	A Rapid Non-Culture-Based Assay for Clinical Monitoring of Phenotypic Resistance of Human Immunodeficiency Virus Type 1 to Lamivudine (3TC). <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 264-270.	3.2	28
735	Detection of HTLV-II proviral sequences in HIV-immunosuppressed patients with HTLV indeterminate serological patterns. <i>Journal of Infection</i> , 1998, 36, 243-244.	3.3	6
736	The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load. <i>Journal of Infection</i> , 1998, 36, 307-311.	3.3	20
737	LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. <i>Virus Research</i> , 1998, 57, 11-20.	2.2	27
738	Lack of benefit or protease inhibitors on HCV viremia in HIV- infected patients. <i>Journal of Hepatology</i> , 1998, 28, 526-527.	3.7	52

#	ARTICLE	IF	CITATIONS
739	Evidence of Nef Truncation in Human Immunodeficiency Virus Type 2 Infection. <i>Journal of Infectious Diseases</i> , 1998, 177, 65-71.	4.0	31
740	Regression of Invasive AIDS-Related Kaposi's Sarcoma Following Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 1998, 26, 218-219.	5.8	20
741	Horizontal and Vertical Transmission of Human Immunodeficiency Virus Type 1 Dual Infections Caused by Viruses of Subtypes B and C. <i>Journal of Infectious Diseases</i> , 1998, 177, 227-231.	4.0	48
742	Sequence Note: Genetic Analysis of Human Immunodeficiency Virus Type 2 Strains from Spain. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 91-94.	1.1	2
743	Letter to the Editor: Phylogenetic Analysis of HIV Type 2 Strains from Portugal. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 471-473.	1.1	5
744	Tropism, Coreceptor Use, and Phylogenetic Analysis of Both the V3 Loop and the Protease Gene of Three Novel HIV-1 Group O Isolates. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 18, 417-425.	0.3	9
745	False positives for HIV using commercial viral load quantification assays. <i>Aids</i> , 1998, 12, 2076-2077.	2.2	18
746	Hepatotoxicity after introduction of highly active antiretroviral therapy. <i>Aids</i> , 1998, 12, 1256.	2.2	180
747	Analysis of pol Gene Heterogeneity, Viral Quasispecies, and Drug Resistance in Individuals Infected with Group O Strains of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 1998, 72, 9002-9015.	3.4	64
748	Opportunistic Infections Shortly after Beginning Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 1998, 3, 229-231.	1.0	29
749	Chemokine receptors and HIV-2. <i>Aids</i> , 1997, 11, 1198-1199.	2.2	22
750	Evidence of HIV-2 Infection in Equatorial Guinea (Central Africa): Partial Genetic Analysis of a B Subtype Virus. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 439-440.	1.1	9
751	Genetic Analysis of an HIV Type 2 Subtype B Virus from a Spanish Individual with AIDS. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 899-900.	1.1	5
752	Reliability of a new recombinant immunoblot assay (RIBA HIV-1/HIV-2 SIA) as a supplemental (confirmatory) test for HIV-1 and HIV-2 infections. <i>Transfusion Science</i> , 1997, 18, 63-69.	0.6	10
753	Co-infection with several HCV genotypes enhances liver damage in patients with chronic hepatitis C. <i>Journal of Infection</i> , 1997, 35, 202-203.	3.3	1
754	Characterization of the Reverse Transcriptase of a Human Immunodeficiency Virus Type 1 Group O Isolate. <i>Virology</i> , 1997, 236, 364-373.	2.4	60
755	A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. <i>Journal of Infection</i> , 1997, 35, 225-230.	3.3	15
756	Hepatitis C Virus Genotypes 1a and 1b Mixed Infections. <i>Vox Sanguinis</i> , 1997, 72, 64-64.	1.5	0

#	ARTICLE	IF	CITATIONS
757	Mycosis fungoides and Sezary syndrome are not associated with HTLV-III infection: an international study. <i>British Journal of Haematology</i> , 1997, 98, 927-933.	2.5	65
758	Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir. <i>Aids</i> , 1997, 11, 1896-1897.	2.2	3
759	Development of a multiplex PCR assay for the simultaneous detection and discrimination of HIV-1, HIV-2, HTLV-I and HTLV-II. <i>Clinical and Diagnostic Virology</i> , 1996, 7, 85-92.	1.7	26
760	First Case of HIV-1 Group O Infection in Spain. <i>Vox Sanguinis</i> , 1996, 71, 66-66.	1.5	34
761	Hepatitis C viraemia in HIV-infected patients. <i>Aids</i> , 1996, 10, 922.	2.2	8
762	High Rate of Indeterminate Reactivity to HTLV in Western Blot Analysis of Spanish Blood Donors ^{>1</sup>. <i>Vox Sanguinis</i>, 1996, 70, 120-121.}	1.5	7
763	Circulating Hepatitis C Virus Genotypes in Spain. <i>Vox Sanguinis</i> , 1996, 70, 180-181.	1.5	10
764	Circulating HIV-1 Serotypes in Spain. <i>Vox Sanguinis</i> , 1996, 70, 236-237.	1.5	2
765	Correlation between Serological and Genetic Methods for Typing Hepatitis C Virus. <i>Vox Sanguinis</i> , 1996, 71, 190-191.	1.5	3
766	Sexual Transmission of Two Different HCV Types Causing Acute Hepatitis C. <i>Vox Sanguinis</i> , 1996, 71, 244-245.	1.5	7
767	Epidemiology of human T-lymphotropic virus type II (HTLV-II) infection in Spain. <i>European Journal of Epidemiology</i> , 1996, 12, 625-629.	5.7	12
768	Interferon α for the Treatment of Chronic Hepatitis C in Patients Infected with Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 1996, 23, 585-591.	5.8	187
769	Epidemiology of HTLV-I Infection in Spain. <i>International Journal of Epidemiology</i> , 1996, 25, 443-449.	1.9	10
770	Sequence Note:envGene Characterization of the First HIV Type 1 Group O Spanish Isolate. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1647-1649.	1.1	21
771	Sequence Note: env Gene Diversity of HIV Type 1 Isolates from Spain. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 955-957.	1.1	8
772	Serial Dilutions on Synthetic Peptide-Based Assays Can Resolve Dual Seroreactivity to HIV-1 and HIV-2. <i>Vox Sanguinis</i> , 1996, 71, 67-68.	1.5	5
773	Efficacy and safety of α -interferon treatment for chronic hepatitis C in HIV-infected patients. <i>Journal of Infection</i> , 1995, 31, 9-13.	3.3	45
774	Ion-pair reversed-phase and low-molecular-weight aqueous gel permeation high-performance liquid chromatography methods for the determination of amoxicillin oligomersa. <i>Chromatographia</i> , 1995, 41, 651-656.	1.3	7

#	ARTICLE	IF	CITATIONS
775	Avoiding false-negative results for HTLV-II using new serological assays. American Journal of Medicine, 1995, 98, 103.	1.5	4
776	High rate of co-infection with different hepatitis C virus subtypes in HIV-infected intravenous drug addicts in Spain. Journal of Hepatology, 1995, 22, 598-599.	3.7	15
777	Sequence Analysis of the V1/V2 and V3 Domains in an HIV-Seronegative AIDS Patient. AIDS Research and Human Retroviruses, 1995, 11, 1539-1541.	1.1	3
778	Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection among Spanish drug users measured by HTLV-1 assay and HTLV-1 and -2 assay. HTLV-1 and HTLV-2 Spanish Study Group. Journal of Clinical Microbiology, 1995, 33, 1735-1738.	3.9	19
779	Phylogenetic relationship and geographic distribution of multiple human T-cell lymphotropic virus type II subtypes. Journal of Virology, 1995, 69, 621-632.	3.4	98
780	Gastrointestinal Leishmaniasis in Human Immunodeficiency Virus-Infected Patients: Report of Five Cases and Review. Clinical Infectious Diseases, 1994, 19, 48-53.	5.8	96
781	Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. Journal of Infection, 1994, 28, 255-259.	3.3	25
782	High morbidity and mortality of chronic viral liver disease in HIV-infected individuals in Spain. Journal of Infection, 1994, 28, 100-102.	3.3	17
783	Significance of HCV RIBA Indeterminate Results in High-Risk Individuals: Assessment by a New Third-Generation RIBA Assay and PCR. Vox Sanguinis, 1994, 66, 148-149.	1.5	9
784	Evaluation of a New Saliva Collection Device for HIV Antibody Screening Purposes. Vox Sanguinis, 1994, 66, 244-244.	1.5	7
785	HIV-1 Causing AIDS and Death in a Seronegative Individual. Vox Sanguinis, 1994, 67, 410-411.	1.5	46
786	Seroreversion in Patients with End-Stage HIV Infection. Vox Sanguinis, 1994, 67, 238-239.	1.5	21
787	HTLV-II Infection among Immigrants to Spain. Vox Sanguinis, 1994, 67, 79-80.	1.5	4
788	Evaluation of a New Fluorescence Immunoassay for CD4+ and CD8+ T Cell Counts in Clinical Samples. Vox Sanguinis, 1994, 67, 86-87.	1.5	5
789	Idiopathic CD4+ T Lymphocytopenia: A Review and Current Perspective. Transfusion Medicine Reviews, 1994, 8, 223-231.	2.0	4
790	Enhanced diagnostic efficiency of the polymerase chain reaction by co-amplification of multiple regions of HIV-1 and HIV-2. Journal of Virological Methods, 1994, 49, 37-46.	2.1	14
791	CD4+ T-lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C. Aids, 1994, 8, 1621.	2.2	48
792	Absence of evidence of retroviral infection in idiopathic CD4+ T-lymphocytopenia syndrome. Aids, 1994, 8, 267.	2.2	4

#	ARTICLE	IF	CITATIONS
793	HIV-2 Infection in high-risk individuals in Spain. <i>Transfusion Science</i> , 1993, 14, 167-172.	0.6	1
794	HTLV-I/II Infections in Spain. <i>International Journal of Epidemiology</i> , 1993, 22, 716-719.	1.9	35
795	Kussmaul respiration and abdominal pain secondary to metabolic acidosis in AIDS patients with disseminated <i>Mycobacterium avium</i> complex infection receiving clofazimine. <i>Aids</i> , 1993, 7, 894.	2.2	1
796	Pyomyositis in patients with HIV infection. <i>Aids</i> , 1993, 7, 1020-1021.	2.2	10
797	Prophylaxis of <i>Pneumocystis carinii</i> pneumonia. <i>Aids</i> , 1993, 7, 1133.	2.2	2
798	Misdiagnosis of HTLV-II infection using HTLV-I screening assays. <i>Aids</i> , 1993, 7, 1395.	2.2	9
799	Insufficiencies of the New WHO Western Blot Criteria in the Diagnosis of HIV-1 and HIV-2 Infections. <i>Vox Sanguinis</i> , 1992, 62, 191-192.	1.5	3
800	Significance of Positive Polymerase Chain Reaction Results in HIV-Seronegative Individuals. <i>Vox Sanguinis</i> , 1992, 63, 287-288.	1.5	2
801	Multifocal splenic abscesses caused by <i>Mycobacterium tuberculosis</i> in HIV-infected drug users. <i>Aids</i> , 1991, 5, 901.	2.2	8
802	Non-Parenteral Transmission of Hepatitis C Virus. <i>International Journal of STD and AIDS</i> , 1991, 2, 449-450.	1.1	0
803	Human Herpesvirus 6 in Spain: Seroprevalence in Blood Donors and Patients with Lymphoproliferative Disorders or HIV Infection. <i>Vox Sanguinis</i> , 1991, 60, 63-64.	1.5	0
804	Synthetic Peptide Immunoassay for Diagnosis of HIV 2 Infection. <i>Vox Sanguinis</i> , 1989, 57, 222-222.	1.5	2
805	HIV-2 in Spanish Drug Abusers. <i>Vox Sanguinis</i> , 1989, 57, 157-157.	1.5	0
806	Serological Markers of Human Immunodeficiency Virus Infection in African Patients with AIDS: Are They Different from Markers Found in Patients from Other Countries?. <i>Journal of Infectious Diseases</i> , 1988, 158, 894-894.	4.0	0